Proteins

Name

Proteins

Accession Number

DBCAT000020

Description

Linear POLYPEPTIDES that are synthesized on RIBOSOMES and may be further modified, crosslinked, cleaved, or assembled into complex proteins with several subunits. The specific sequence of AMINO ACIDS determines the shape the polypeptide will take, during PROTEIN FOLDING, and the function of the protein.

Drugs

Drug	Drug Description
Lepirudin	A protein-based direct thrombin inhibitor used as an anticoagulant in patients with heparin-induced thrombocytopenia.
Cetuximab	An endothelial growth factor receptor binding fragment used to treat colorectal cancer as well as squamous cell carcinoma of the head and neck.
Dornase alfa	A synthetic form of human deoxyribonuclease I used to break down extracellular DNA in the lungs, a major source of mucous viscosity in cystic fibrosis.
Denileukin diftitox	A recombinant cytotoxic protein based on a combination of diphtheria toxin fragments and interleukin-2 used to treat cutaneous T-cell lymphoma by targeting the interleukin-2 receptor.
Etanercept	A protein therapy based on the binding fragment of the tumour necrosis factor alpha receptor used to treat severe rheumatoid arthritis and moderate to severe plaque psoriasis.
Leuprolide	A peptide-based GnRH receptor superagonist used for the palliative treatment of prostate cancer, uterine leiomyomata, endometriosis, and central precocious puberty.
Peginterferon alfa-2a	A modified form of recombinant human interferon used to stimulate the innate antiviral response in the treatment of hepatitis B and C viruses.
Alteplase	A recombinant form of human tissue plasminogen activator used in the emergency treatment of myocardial infarction, ischemic stroke, and pulmonary emboli.
Interferon alfa-n1	A purified form of human interferon used to stimulate the innate antiviral response in the treatment of genital warts due to human papilloma virus.
Darbepoetin alfa	A recombinant form of human erythropoietin used to increase differentiation of progenitor cells to red blood cells in the treatment of anemia.
Urokinase	A low molecular weight form of human urokinase used to treat pulmonary embolism and myocardial infarction as well as to clear IV lines.
Reteplase	A purified form of human tissue plasminogen activator used in the emergency treatment of myocardial infarction, ischemic stroke, and pulmonary emboli.
Erythropoietin	A recombinant form of human erythropoietin used to increase differentiation of progenitor cells to red blood cells in the treatment of anemia.
Salmon calcitonin	A synthetic peptide form of calcitonin used to inhibit bone resorption in the treatment of hypercalcemia, osteoporosis, and Paget's disease.
Interferon alfa-n3	A purified form of human interferon used to stimulate the innate antiviral response in the treatment of genital warts due to human papilloma virus.
Pegfilgrastim	A recombinant human granulocyte colony stimulating factor used to stimulate the production of neutrophils and prevent febrile neutropenia or infections after myelosuppressive chemotherapy.
Sargramostim	A modified form of recombinant human granulocyte-macrophage colony stimulating factor used to increase immune cell production after myelosuppressive therapy or bone marrow transplant.
Peginterferon alfa-2b	A purified form of human interferon used to stimulate the innate antiviral response in the treatment of hepatitis B and C, genital warts, and some cancers.
Antihemophilic factor, human recombinant	A form of recombinant coagulation Factor VIII used to treat hemophilia A, von Willebrand disease, and Factor XIII deficiency.
Anakinra	A recombinant form of human interleukin-1 receptor antagonist used in the treatment of rheumatoid arthritis, neonatal-onset multisystem inflammatory disease and deficiency of interleukin-1 receptor antagonist (DIRA).
Gramicidin D	A bactericidal antibiotic used in the treatment of dermatological and ophthalmic infections.
Human immunoglobulin G	A purified form of human immunoglobulin G and other proteins used to treat immunodeficiency and a wide variety of autoimmune disorders.
Interferon gamma-1b	重组人干扰素用于混乱关系的一种形式at infections associated with chronic granulomatous disease and to slow the progression of severe malignant osteopetrosis.
Desmopressin	A synthetic analog of vasopressin used to reduce renal excretion of water in central diabetes insipidus and nocturia.
Coagulation factor VIIa Recombinant Human	A form of recombinant human coagulation Factor VII used to treat hemophilia A and B.
Palifermin	A form of recombinant human keratinocyte growth factor used to prevent and treat oral mucositis following radiation or chemotherapy.
Glucagon	A form of recombinant glucagon used to treat hypoglycemia in diabetes mellitus and as a part of gastrointestinal imaging procedures.
Aldesleukin	A recombinant analog of interleukin-2 used to induce an adaptive immune response in the treatment of renal cell carcinoma.
Botulinum toxin type B	A purified form of botulinum toxin type B used to block acetylcholine release in the treatment of cervical dystonia and sialorrhea.
Omalizumab	A monoclonal anti-immunoglobulin E antibody used in the treatment of severe asthma and chronic idiopathic urticaria.
Adalimumab	A monoclonal anti-tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn's disease, and ankylosing spondylitis.
Abciximab	A monoclonal anti-glycoprotein IIb/IIIa receptor antibody used to prevent thrombosis during percutaneous coronary intervention.
Gemtuzumab ozogamicin	A monoclonal anti-CD33 antibody used to treat CD33-positive acute myeloid leukemia.
Indium In-111 satumomab pendetide	For diagnosis of extrahepatic malignant cancers
Alpha-1-proteinase inhibitor	A purified form of human alpha-1 proteinase inhibitor used to treat emphysema patients with associated alpha-1 proteinase inhibitor deficiency.
Albumin human	A purified form of human serum albumin used to replace lost albumin in patients with hypoalbuminemia, to treat hypovolemia and ascites, and as a part of some diagnostic imaging kits.
Infliximab	A monoclonal anti tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn's disease, and ankylosing spondylitis.
Follitropin	A form of recombinant human follicle stimulating hormone used to stimulate follicle development in women with primary ovarian hypogonadism and in men with hypogonadotropic hypogonadism.
Vasopressin	A peptide hormone used to increase blood pressure in patients with vasodilatory shock who are resistant to fluid and catecholamine therapy.
Interferon beta-1b	A form of recombinant human interferon used to slow the progression of relapsing multiple sclerosis and to reduce the frequency of clinical symptoms.
Insulin pork	A purified form of porcine insulin used to control hyperglycemia in diabetes mellitus.
Trastuzumab	A monoclonal anti-human epidermal growth factor receptor 2 protein antibody used to treat HER2-positive breast, gastroesophageal, and gastric cancers.
Rituximab	A monoclonal anti-CD20 antibody used to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia, Wegener's granulomatosis, pemphigus vulgaris, and rheumatoid arthritis.
Basiliximab	A monoclonal anti-C25 antibody (interleukin-2 receptor alpha subunit) used as immunosuppressive therapy in kidney transplant patients.
Muromonab	A monoclonal anti-CD3 antibody used as immunosuppressive therapy in kidney, heart, and liver transplant patients.
Ibritumomab tiuxetan	A monoclonal anti-CD20 antibody used to treat B-cell non-Hodgkin's lymphoma via a conjugated radioactive isotope.
Tositumomab	A monoclonal anti-CD20 antibody used to treat B-cell non-Hodgkin's lymphoma via a conjugated radioactive isotope.
Botulinum toxin type A	A purified form of botulinum toxin type A used to block acetylcholine release in the treatment of chronic sialorrhea, muscle spasticity, and dystonia, as well as in cosmetic applications.
Alemtuzumab	A monoclonal anti-CD52 antibody used in the treatment of B-cell chronic lymphocytic leukemia and relapsing forms of multiple sclerosis.
Capromab pendetide	A monoclonal anti-prostate specific membrane antigen antibody used in imaging kits to target radioactive agents to malignant prostate tissue.
Efalizumab	A monoclonal anti-CD11a antibody used to treat moderate to severe plaque psoriasis.
Antithymocyte immunoglobulin (rabbit)	A purified form of rabbit anti-thymocyte antibodies used for immunosuppression in patients receiving kidney transplants.
Filgrastim	A form of recombinant human granulocyte colony stimulating factor used to induce the production of granulocytes and lower infection risk after myelosuppressive therapy.
Becaplermin	A recombinant form of human platelet-derived growth factor used to treat ulcers due to diabetic neuropathy in the lower extremities when there is adequate blood supply to the area.
Agalsidase beta	A recombinant human alpha-galactosidase indicated to treat Fabry disease, a genetic deficiency in the enzyme leading to buildup of globotriaosylceramide.
Natalizumab	A monoclonal anti-integrin antibody which binds to the alpha 4 subunit of integrins to prevent migration of immune cells, and is used to treat Crohn's disease or multiple sclerosis.
Enfuvirtide	An HIV-1 gp41 fusion inhibitor used in patients experiencing HIV-1 replication who are already being treated with other anti-retrovirals.
Palivizumab	A monoclonal anti respiratory syncytial virus F protein antibody used to prevent serious sequelae caused by respiratory syncytial virus infection in pediatric patients.
Daclizumab	A monoclonal anti-CD25 antibody that blocks the interleukin-2 receptor which is used to treat relapsing forms of multiple sclerosis.
Bevacizumab	A monoclonal anti-vascular endothelial growth factor antibody used in combination with antineoplastic agents for the treatment of many types of cancer.
Technetium Tc-99m arcitumomab	For imaging colorectal tumors
Pentagastrin	A gastrin-like molecule used as a diagnostic aid for the evaluation of gastric acid secretory function, gastric hypersecretion, and Zollinger-Ellison tumors.
Eculizumab	A recombinant humanized monoclonal antibody used to reduce the risk of hemolysis in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).
Panitumumab	A recombinant humanized monoclonal antibody used to treat EGFR-expressing, metastatic colorectal carcinoma that is refractory to fluoropyrimidine-, oxaliplatin-, and irinotecan- containing chemotherapy regimens.
Ranibizumab	A recombinant humanized monoclonal antibody and VEGF-A antagonist used for the management of macular edema after retinal vein occlusion, age-related macular degeneration (wet), and diabetic macular edema.
Mecasermin	A recombinant insulin-like growth factor-1 used for the long-term treatment of growth failure in pediatric patients with primary IGF-1 deficiency or with growth hormone gene deletion due to the development of neutralizing antibodies to GH.
Insulin glulisine	A short-acting form of insulin used for glycemic control in type 1 and type 2 diabetes mellitus.
Galiximab	Investigated for use/treatment in lymphoma (non-hodgkin's), psoriasis and psoriatic disorders, bone metastases, multiple myeloma, prostate cancer, and rheumatoid arthritis.
Afamelanotide	An injectable subcutaneous implant used to mitigate phototoxicity secondary to erythropoietic protoporphyria (EPP).
Pexelizumab	For the treatment of inflammation during cardiac surgery.
Afelimomab	调查使用/治疗脓毒症和解剖cemia.
Epratuzumab	Investigated for use/treatment in leukemia (lymphoid), lymphoma (non-hodgkin's), and systemic lupus erythematosus.
Bectumomab	Investigated for use/treatment in lymphoma (non-hodgkin's).
Oregovomab	Investigated for use/treatment in ovarian cancer.
IGN311	Intended for the treatment of various forms of cancer.
Adecatumumab	Investigated for use/treatment in breast cancer and prostate cancer.
Labetuzumab	Labetuzumab is a humanized monoclonal antibody used to treat cancer. Retrieved from "http://en.wikipedia.org/wiki/Labetuzumab"
Matuzumab	Investigated for use/treatment in cervical dysplasia/cancer, colorectal cancer, gastric cancer, and lung cancer.
Fontolizumab	Investigated for use/treatment in crohn's disease and psoriasis and psoriatic disorders.
Bavituximab	Investigated for use/treatment in breast cancer, cancer/tumors (unspecified), HIV infection, hepatitis (viral, C), and solid tumors.
CR002	Investigated for use/treatment in nephropathy.
Rozrolimupab	Investigated for use/treatment in thrombocytopenia.
Hepatitis B immune globulin	An injection of immunoglobulin G (IgG) antibodies to prevent the development of chronic Hepatitis B infection.
Oportuzumab monatox	Investigated for use/treatment in bladder cancer and head and neck cancer.
Obiltoxaximab	A monoclonal antibody used for prophylaxis or treatment of inhalational anthrax.
XTL-001	Investigated for use/treatment in hepatitis (viral, B).
NAV 1800	Investigated for use/treatment in colorectal cancer and solid tumors.
Briakinumab	Investigated for use/treatment in autoimmune diseases, crohn's disease, multiple sclerosis, psoriasis and psoriatic disorders, and rheumatoid arthritis.
Otelixizumab	Investigated for use/treatment in diabetes mellitus type 1, pediatric indications, and psoriasis and psoriatic disorders.
AMG 108	Investigated for use/treatment in osteoarthritis and rheumatoid arthritis.
Iratumumab	Investigated for use/treatment in lymphoma (unspecified).
Enokizumab	Investigated for use/treatment in asthma.
Ramucirumab	An antineoplastic agent and direct VEGFR2 (vascular endothelial growth factor receptor 2) antagonist that blocks the binding of natural VEGF ligands, which are secreted by solid tumors to promote angiogenesis and enhance tumor blood supply.
Farletuzumab	Investigated for use/treatment in ovarian cancer.
Veltuzumab	Investigated for use/treatment in lymphoma (non-hodgkin's).
Ustekinumab	A targeted antibody therapy used to manage inflammatory conditions such as plaque psoriasis, psoriatic arthritis, Crohn's Disease, and ulcerative colitis.
Trastuzumab emtansine	An antineoplastic agent and antibody-drug conjugate used to treat HER2-overexpressing breast cancer.
PRO-542	Investigated for use/treatment in acquired immune deficiency syndrome (AIDS) and aids-related infections, HIV infection, and pediatric indications.
TNX-901	Investigated for use/treatment in allergic reaction.
Inotuzumab ozogamicin	An antibody-drug conjugate used to treat B-cell precursor acute lymphoblastic leukemia (ALL).
RI 624	Investigated for use/treatment in pain (acute or chronic).
Stamulumab	Investigated for use/treatment in muscular dystrophy.
Leronlimab	A humanized monoclonal antibody being investigated
Glembatumumab vedotin	Investigated for use/treatment in melanoma.
Olaratumab	血小板源生长因子受体α提单ocking antibody used with doxorubicin to treat patients with certain types of soft tissue sarcoma (STS).
IPH 2101	Investigated for use/treatment in leukemia (myeloid) and multiple myeloma.
TB-402	Investigated for use/treatment in atrial fibrillation and thrombosis.
Caplacizumab	A von Willebrand factor (vWF)-directed antibody fragment used to treat acquired thrombotic thrombocytopenic purpura (aTTP).
IMC-1C11	Investigated for use/treatment in cancer/tumors (unspecified).
Eldelumab	Investigated for use/treatment in ulcerative colitis.
Lumiliximab	Investigated for use/treatment in asthma and leukemia (lymphoid).
Canakinumab	An interleukin-1β blocker used to treat Periodic Fever Syndromes such as Cryopyrin-Associated Periodic Syndromes (CAPS) and Familial Mediterranean Fever (FMF), and also to treat active Systemic Juvenile Idiopathic Arthritis (SJIA).
Ipilimumab	人类细胞毒性t淋巴球抗原4 (CTLA-4)blocking antibody used to treat metastatic or unresectable melanoma.
Nimotuzumab	An EGFR-targeting monoclonal antibody used in the treatment of squamous cell carcinomas of the head and neck and glioblastomas.
Clenoliximab	Investigated for use/treatment in rheumatoid arthritis.
Tocilizumab	An interleukin-6 (IL-6) receptor antagonist used to treat Cytokine Release Syndrome (CRS), Systemic Juvenile Idiopathic Arthritis (sJIA), Giant Cell Arteritis (GCA), and Rheumatoid Arthritis (RA).
BIIB015	Investigated for use/treatment in solid tumors.
Motavizumab	Investigated for use/treatment in viral infection and pediatric indications.
Elotuzumab	An antineoplastic agent and SLAMF7-directed immunostimulatory antibody used for the treatment of refractory multiple myeloma in combination with other antineoplastic agents.
AVE9633	Investigated for use/treatment in leukemia (myeloid).
Carotuximab	Investigated for use/treatment in solid tumors.
XmAb 2513	Investigated for use/treatment in lymphoma (unspecified) and lymphoma (non-hodgkin's).
Coltuximab ravtansine	Investigated for use/treatment in lymphoma (non-hodgkin's).
Teprotumumab	A fully human monoclonal antibody directed against insulin-like growth factor-1 receptor for the treatment of thyroid eye disease.
Lucatumumab	Investigated for use/treatment in leukemia (lymphoid), multiple myeloma, and lymphoma (unspecified).
Pertuzumab	An antineoplastic agent used in the treatment of HER2-positive metastatic breast cancer in combination with other antineoplastic agents.
Siplizumab	Investigated for use/treatment in psoriasis and psoriatic disorders, transplant (rejection), graft versus host disease, lymphoma (unspecified), and leukemia (unspecified).
Human C1-esterase inhibitor	A C1 inhibitor used to prevent angioedema attacks associated with hereditary angioedema.
Apolizumab	Investigated for use/treatment in lymphoma (non-hodgkin's), leukemia (lymphoid), and solid tumors.
Sibrotuzumab	Investigated for use/treatment in cancer/tumors (unspecified), colorectal cancer, and lung cancer.
Bivatuzumab	Investigated for use/treatment in cancer/tumors (unspecified) and head and neck cancer.
Lerdelimumab	Investigated for use/treatment in glaucoma and cataracts.
Lexatumumab	Investigated for use/treatment in cancer/tumors (unspecified).
Reslizumab	An IL-5 antagonist used as an add-on maintenance treatment of patients with severe eosinophilic asthma in adults.
Teplizumab	A humanized IgG1κ Fc-nonbinding anti-CD3 monoclonal antibody currently under development as an immune therapy to prolong progression to type 1 diabetes in high-risk patients.
Catumaxomab	For use in the management of malignant ascites tumours via intraperitoneal infusion where standard therapy is not available or feasible [FDA Label].
Mepolizumab	A fully-humanized monoclonal IgG1 kappa anti-IL-5 antibody used in conjunction with other therapies to treat severe asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome.
Denosumab	A RANK ligand (RANKL) inhibitor used for the management of osteoporosis in patients at high risk for bone fractures.
Volociximab	Investigated for use/treatment in solid tumors, renal cell carcinoma, melanoma, pancreatic cancer, lung cancer, and ovarian cancer.
Ofatumumab	An anti-CD20 antibody used for the treatment of chronic lymphocytic leukemia (CLL) in selected patients with certain treatment histories and responsiveness to anticancer medications.
Liraglutide	A GLP-1 analog used in the management of type 2 diabetes mellitus and prevention of cardiovascular complications associated with diabetes.
Golimumab	A TNFα inhibitor used in the symptomatic treatment of various active inflammatory disorders, such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis.
Aprotinin	A serine protease inhibitor used to reduce the risk for perioperative blood loss and the need for blood transfusion in high-risk patients during cardiopulmonary bypass for coronary artery bypass graft surgery.
Brentuximab vedotin	A CD30-directed antibody-drug conjugate used to treat various types of lymphoma.
Belimumab	A B-lymphocyte stimulator (BLyS)-specific inhibitor used to treat systemic lupus erythematosus and active lupus nephritis as an add-on therapy.
Raxibacumab	A monoclonal antibody used in conjunction with an antibacterial regimen to treat patients with inhalational anthrax caused by Bacillus anthracis and for prophylaxis of inhalational anthrax when appropriate.
Certolizumab pegol	A tumor necrosis factor (TNF) blocker used to treat a variety of autoimmune and autoinflammatory conditions like Crohn's disease, rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis, and plaque psoriasis.
Obinutuzumab	一种抗肿瘤药CD20抗体用于治疗untreated chronic lymphocytic leukemia in combination with chlorambucil.
Secukinumab	An immunomodulating agent and interleukin antagonist used to manage plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, along with other joint inflammatory disorders.
Vedolizumab	An integrin blocker and anti-inflammatory agent used to manage ulcerative colitis and Crohn's disease in adults with inadequate clinical response to immunomodulators.
Nivolumab	A PD-1 blocking antibody used to treat melanoma, non small-cell lung cancer, renal cell cancer, head and neck cancer, and Hodgkin lymphoma.
Siltuximab	An interleukin antagonist used to treat multicentric Castleman's disease (MCD) in patients who are HIV and HHV-8 negative.
Pembrolizumab	A PD-1 blocking antibody used to treat various types of cancer, including metastatic melanoma, non small-cell lung cancer, cervical cancer, head and neck cancer, and Hodgkin's lymphoma.
Dulaglutide	A GLP-1 agonist used to manage type 2 diabetes mellitus.
Metreleptin	A leptin analogue used as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.
Blinatumomab	An antineoplastic antibody used to treat Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
Dinutuximab	An immunotherapeutic agent used in combination with other immunomodulating agents to treat high-risk neuroblastoma in pediatric patients who achieve at least a partial response to prior first-line multiagent, multimodality therapy.
Asfotase alfa	An enzyme replacement therapy used for the treatment of perinatal/infantile and juvenile onset hypophosphatasia (HPP).
Peginterferon beta-1a	An interferon beta used to treat relapsing forms of multiple sclerosis.
Protamine sulfate	A blood factor used when the reversal of the anticoagulant effect of heparin is necessary and for the treatment of heparin overdose.
Idarucizumab	抗体结合dabigatran逆转of anticoagulant effects of dabigatran.
Alirocumab	A PCSK9 inhibitor used as an adjunct to manage heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in patients who require additional lowering of LDL-cholesterol (LDL-C).
Evolocumab	A PCSK9 (proprotein convertase subtilisin kexin type 9) inhibitor antibody used as an adjunct to LDL cholesterol reducing therapies, aiding in the prevention of cardiovascular events and cardiovascular revascularization procedures.
Daratumumab	A CD38-directed cytolytic antibody used alone or as an adjunct drug in the treatment of multiple myeloma and light chain amyloidosis.
Necitumumab	A monoclonal antibody used to treat metastatic squamous non-small cell lung cancer.
Casein	An extract from Casein used in allergy testing.
Thioredoxin	Thioredoxin is a small dithiol protein and specific reductant for major allergenic proteins present in foods from animal and plant products. It is a 12-kD oxidoreductase enzyme encoded by TXN...
Protein C	A medication used to treat protein C deficiency leading to purpura fulminans or coumarin-induced skin necrosis.
Ixekizumab	A monoclonal antibody used to treat moderate to severe plaque psoriasis.
Atezolizumab	A monoclonal antibody used to treat advanced or metastatic urothelial carcinoma with disease progression during or up to 12 months after platinum-containing chemotherapy.
Antithrombin III human	An alpha-2-glycoprotein used to prevent thromboembolisms in patients with hereditary antithrombin III deficiency.
Human varicella-zoster immune globulin	A solution of antibodies used for post exposure prophylaxis of varicella infections in high risk populations, as well as to reduce the severity of infections.
Conatumumab	Conatumumab has been used in trials studying the treatment of Sarcoma, Lymphoma, Oncology, Colon Cancer, and Rectal Cancer, among others.
Bremelanotide	Bremelanotide is indicated to treat premenopausal women with hypoactive sexual desire disorder that is not due to a medical or psychiatric condition, problems with the relationship, or the effects of...
Tabalumab	Tabalumab has been used in trials studying the treatment of Autoimmune Disease, Rheumatoid Arthritis, Kidney Failure, Chronic, Connective Tissue Disease, and Systemic Lupus Erythematosus, among others.
Ficlatuzumab	Ficlatuzumab has been used in trials studying the treatment of Acute Myeloid Leukemia, Non-small Cell Lung Cancer, Mullerian Mixed Tumor of Ovary, Relapsed Acute Myeloid Leukemia, and Refractory Acute Myeloid...
Figitumumab	Figitumumab has been used in trials studying the treatment of Sarcoma, Solid Tumor, Breast Cancer, Lung Neoplasms, and Advanced Cancer, among others.
Setmelanotide	Setmelanotide is indicated to treat obesity caused by genetic POMC, PCSK1, or LEPR deficiencies or Bardet-Biedl syndrome.
Durvalumab	An antineoplastic monoclonal antibody used to treat urothelial carcinoma and locally advanced, unresectable non-small cell lung cancer.
Bapineuzumab	Bapineuzumab has been investigated for the treatment of Alzheimer's Disease.
Onartuzumab	Onartuzumab has been used in trials studying the treatment of Neoplasms, Lung Cancer, Glioblastoma, Gastric Cancer, and Colorectal Cancer, among others.
Solanezumab	Solanezumab is under investigation for the treatment of Dementia, Alzheimers Disease, and Alzheimers Disease, Familial.
Sarilumab	A monoclonal antibody used to treat moderate to severe rheumatoid arthritis who have responded poorly or are intolerant of other DMARDs.
Tremelimumab	Tremelimumab is under investigation for the treatment of Mesothelioma, Liver Cancer, Liver Neoplasms, Liver Cell Caricinoma, and HepatoCellular Carcinoma. Tremelimumab has been investigated in Part C: Malignant Mesothelioma and Part...
Brodalumab	A monoclonal antibody used to treat moderate to severe plaque psoriasis.
Sirukumab	Sirukumab has been used in trials studying the treatment and basic science of Giant Cell Arteritis and Arthritis, Rheumatoid.
Lampalizumab	Lampalizumab has been used in trials studying the treatment of Geographic Atrophy.
Guselkumab	A monoclonal antibody used to treat moderate to severe plaque psoriasis.
Dalotuzumab	Dalotuzumab has been investigated for the treatment of Breast Cancer, Non Small Cell Lung Cancer, and Metastatic Colorectal Cancer.
Emibetuzumab	Emibetuzumab has been used in trials studying the treatment of Advanced Cancer, Renal Cell Carcinoma, Hepatocellular Cancer, Gastric Adenocarcinoma, and Non-Small Cell Lung Cancer, among others.
Ligelizumab	一个在investig IgE-directed单克隆抗体ation for the treatment of chronic spontaneous urticaria (CSU).
Seribantumab	Seribantumab has been used in trials studying the treatment of NSCLC, Heregulin, Adenocarcinoma, Colorectal Cancer, and Solid Tumor Cancers, among others.
Landogrozumab	Landogrozumab has been used in trials studying the treatment of Advanced Cancer, Muscular Atrophy, and Pancreatic Cancer.
Romosozumab	A monoclonal antibody used to treat osteoporosis in postmenopausal women at high risk of fracture, patients who are intolerant of other treatments, or patients who have failed other treatments.
Avelumab	A monoclonal antibody used to treat metastatic merkel cell carcinoma, metastatic urothelial carcinoma, or renal cell carcinoma.
Crenezumab	Crenezumab has been used in trials studying the treatment of Alzheimer's Disease.
Rilotumumab	Rilotumumab has been investigated for the treatment of Cancer, Lung Cancer, Solid Tumors, Gastric Cancer, and Prostate Cancer, among others.
Anifrolumab	A monoclonal antibody that inhibits type 1 interferon receptors, indicated in the treatment of moderate to severe systemic lupus erythematosus.
Ocrelizumab	A CD20 specific monoclonal antibody used to treat relapsing remitting multiple sclerosis.
Gantenerumab	A fully human IgG1κ monoclonal antibody with specificity for amyloid-beta oligomers and fibrils under investigation for the treatment of Alzheimer's disease.
Visilizumab	Visilizumab has been investigated for the treatment of Ulcerative Colitis.
Lorvotuzumab mertansine	Lorvotuzumab mertansine has been used in trials studying the treatment of SCLC, Leukemia, Ovarian Cancer, Multiple Myeloma, and Merkel Cell Carcinoma, among others.
Patritumab	Patritumab has been used in trials studying the treatment of LUNG CANCER, Solid Tumors, Neoplasms by Site, Head and Neck Neoplasms, and Non-small Cell Lung Cancer, among others.
Fulranumab	Fulranumab被用于试验研究treatment of Pain, Cystitis, Neuralgia, Joint Pain, and Arthralgia, among others.
Tarextumab	Tarextumab has been used in trials studying the treatment of Solid Tumors, Stage IV Pancreatic Cancer, and Stage IV Small Cell Lung Cancer.
Sotatercept	Sotatercept has been used in trials studying the supportive care and treatment of Anemia, Leukemia, Solid Tumors, Bladder Cancer, and multiple myeloma, among others.
Gevokizumab	Gevokizumab has been used in trials studying the treatment of Acne Vulgaris, Osteoarthritis, Behcet's Uveitis, Pyoderma Gangrenosum, and Behcet's Disease Uveitis, among others. Gevokizumab acts as a modulator of cytokine...
Duligotuzumab	Duligotuzumab has been used in trials studying the treatment of Neoplasms, Colorectal Cancer, Head and Neck Cancer, and Epithelial Tumors, Malignant.
Dupilumab	A monoclonal antibody used to treat moderate to severe atopic dermatitis, asthma, and nasal polyps accompanied by chronic rhinosinusitis in adolescents and adults.
Tralokinumab	A monoclonal antibody directed against interleukin-13 which is used in the treatment of moderate-to-severe atopic dermatitis in patients requiring systemic therapy.
Etrolizumab	A humanized IgG1κ anti-β7 integrin subunit monoclonal antibody under investigation for use in ulcerative colitis and Crohn's disease.
Ganitumab	Ganitumab has been used in trials studying the treatment of Colon Cancer, Rectal Cancer, Breast Cancer, Breast Tumors, and Breast Neoplasms, among others.
Etaracizumab	Etaracizumab has been investigated for the treatment of Psoriasis, Renal Cell Carcinoma, Stage IV Renal Cell Cancer, Recurrent Renal Cell Cancer, and Stage III Renal Cell Cancer.
Polatuzumab vedotin	A CD79b antibody conjugate indicated to treat relapsed or refractory B-cell lymphoma.
Inclacumab	Inclacumab has been used in trials studying the treatment and prevention of Myocardial Infarction, Peripheral Arterial Disease (PAD), and Coronary Heart Disease, Graft Occlusion, Vascular.
Cixutumumab	Cixutumumab has been used in trials studying the treatment of Lung Cancer, Malignant Neoplasm, Leukemia, Mast-Cell, Non-Small-Cell Lung Carcinoma, and Adenocarcinoma of the Prostate. Cixutumumab is a highly specific recombinant...
Ascrinvacumab	Ascrinvacumab has been used in trials studying the treatment and basic science of Neoplasms, Advanced Solid Tumors, Carcinoma, Hepatocellular, and Malignant Pleural Mesothelioma.
Aducanumab	A monoclonal antibody indicated in the treatment of Alzheimer's disease.
Tanezumab	Tanezumab has been investigated for the treatment of Osteoarthritis, Knee and Neuralgia, Postherpetic.
Dusigitumab	Dusigitumab has been used in trials studying the treatment of Cancer, Advanced Solid Malignancies, Unresectable or Metastatic Hepatocellular Carcinoma (HCC), and Hormone-sensitive, HER-2 Negative Metastatic Breast Cancer.
Fresolimumab	Fresolimumab has been used in trials studying the treatment of Primary Brain Tumors, Metastatic Breast Cancer, Diffuse Systemic Sclerosis, Pleural Malignant Mesothelioma, and Primary Focal Segmental Glomerulosclerosis.
Bococizumab	Bococizumab has been used in trials studying the treatment and prevention of Dyslipidemia, Hyperlipidemia, Hypercholesterolemia, Cardiovascular Disease, and Heterozygous Familial Hypercholesterolemia.
Mirvetuximab Soravtansine	Mirvetuximab Soravtansine has been used in trials studying the treatment of Ovarian cancer, Endometrial Cancer, Fallopian tube cancer, Epithelial Ovarian Cancer, and Primary Peritoneal Cancer, among others.
Mogamulizumab	A monoclonal antibody used to treat relapsed or refractory mycosis fungoides or Sézary syndrome after attempting one other therapy.
Inebilizumab	A humanized anti-CD19 cytolytic monoclonal antibody for B-cell depletion in autoimmune conditions. Currently approved only for neuromyelitis optica spectrum disorder (NMOSD).
Mavrilimumab	Mavrilimumab has been investigated for the treatment of Rheumatoid Arthritis.
Blosozumab	Blosozumab has been used in trials studying the basic science and treatment of Osteoporosis and Osteoporosis, Postmenopausal.
Bimagrumab	Bimagrumab has been used in trials studying the treatment and supportive care of Sarcopenia, Skeletal Muscle, Mechanical Ventilation, Sporadic Inclusion Body Myositis, and Sporadic Inclusion Body Myositis (sIBM), among others.
Dacetuzumab	Investigated for use/treatment in lymphoma (non-hodgkin's) and multiple myeloma.
Tovetumab	Tovetumab has been used in trials studying the treatment of Cancer, Glioblastoma Multiforme, and Advanced Solid Malignancies.
Ibalizumab	A CD4-specific antibody used to treat HIV infections.
Intetumumab	Intetumumab has been used in trials studying the treatment of Melanoma.
Carlumab	Carlumab has been used in trials studying the treatment of Cancer and Prostate Cancer.
Demcizumab	Demcizumab is under investigation for the treatment of Nonsquamous Nonsmall Cell Neoplasm of Lung.
Abituzumab	Abituzumab has been used in trials studying the treatment of Prostate Cancer Metastatic.
Naptumomab estafenatox	Naptumomab Estafenatox has been used in trials studying the treatment of Pancreatic Cancer, Renal Cell Carcinoma, and Non-Small-Cell Lung Carcinoma.
Crotedumab	Crotedumab has been used in trials studying the treatment of Diabetes Mellitus, Type 2.
Concizumab	Concizumab has been used in trials studying the treatment of Haemophilia A and Congenital Bleeding Disorder.
Depatuxizumab	Depatuxizumab has been used in trials studying the treatment and diagnostic of Adenocarcinoma and Advanced Solid Tumors.
Rontalizumab	Rontalizumab has been used in trials studying the treatment of Systemic Lupus Erythematosus.
Amatuximab	Amatuximab has been used in trials studying the treatment and basic science of Mesothelioma, Ovarian Cancer, Ovarian Neoplasms, Pancreatic Cancer, and Mesothelioma, Malignant, among others.
Clazakizumab	Clazakizumab has been used in trials studying the treatment of Rheumatoid Arthritis.
Ozanezumab	Ozanezumab has been used in trials studying the treatment of Multiple Sclerosis, Amyotrophic Lateral Sclerosis, and Multiple Sclerosis, Relapsing-Remitting.
Sacituzumab govitecan	Sacituzumab govitecan targets TROP-2-expressing cancer cells through a humanized antibody (RS7) before subsequently becoming internalized and releasing the topoisomerase I inhibitor SN-38 to induce DNA damage-mediated apoptosis.
Milatuzumab	Milatuzumab has been used in trials studying the treatment of Lupus Nephritis, Multiple Myeloma (MM), GVHD (Acute or Chronic), Myelodysplastic Syndrome, and Chronic Lymphocytic Leukemia, among others.
Robatumumab	Robatumumab has been used in trials studying the treatment of Osteosarcoma, Sarcoma, Ewing's, and Peripheral Neuroectodermal Tumor.
Racotumomab	Racotumomab has been used in trials studying the treatment of Glioma, Wilm's Tumor, Neuroblastoma, Retinoblastoma, and Ewing's Sarcoma.
Olokizumab	A humanized anti-IL-6 IgG4κ antibody under investigation for use in autoimmune conditions including rheumatoid arthritis.
Edrecolomab	Not Annotated
Nebacumab	Not Annotated
Human cytomegalovirus immune globulin	A solution of immune globulin G against cytomegalovirus used to prevent transmission of cytomegalovirus after organ transplants.
Emicizumab	An antibody against Factor IXa and Factor X used to treat hemophilia A.
Semaglutide	A glucagon-like peptide 1 receptor agonist used to improve glycemic control in type 2 diabetes mellitus.
Sulesomab	Market product is Tc99m-labeled murine antibody fragment for nuclear imaging of activated granulocytes.
Besilesomab	A monoclonal antibody bound to technetium-99 used to find infection and inflammation in patients with suspected osteomyelitis.
Tildrakizumab	An interleukin-23 antagonist used to treat moderate to severe plaque psoriasis.
Erenumab	A calcitonin-gene related peptide antagonist used to prevent migraines.
Fremanezumab	A humanized monoclonal antibody directed against human calcitonin-gene related peptide to prevent migraines.
Fanolesomab	An anti-SSEA-1 monoclonal antibody used for imaging of the appendix and to diagnose appendicitis.
Lanadelumab	A plasma kallikrein inhibitor used to treat attacks of hereditary angioedema.
Moxetumomab pasudotox	A CD22-specific antibody conjugated to a truncated exotoxin used to treat relapsed or refractory hairy cell leukemia in patients who have already been treated with a purine nucleoside analog and one other treatment.
Elapegademase	A recombinant adenosine deaminase used to treat adenosine deaminase severe combined immune deficiency.
Lebrikizumab	Lebrikizumab has been used in trials studying the treatment of Asthma, Allergic Asthma, Atopic Dermatitis, Idiopathic Pulmonary Fibrosis, and COPD, Chronic Obstructive Pulmonary Disease.
Benralizumab	A monoclonal antibody used to treat eosinophilic asthma.
Zalutumumab	Zalutumumab is a fully human IgG1 monoclonal antibody designed to bind with selectivity to the epidermal growth factor receptor (EGFR). Zalutumumab has been investigated for the treatment of Squamous Cell...
Plozalizumab	Plozalizumab has been investigated for the treatment of Atherosclerosis. Plozalizumab, a novel humanized monoclonal antibody, specifically targets CCR2 chemokine receptors found on the surface of certain white blood cells including...
Sifalimumab	Sifalimumab is a fully human monoclonal antibody targeting interferon-alpha. The levels of interferon-alpha are elevated in many patients with active systemic lupus erythematosus (SLE, or lupus) and other autoimmune disorders,...
Emapalumab	An interferon gamma blocking antibody used to treat primary hemophagocytic lymphohistiocytosis.
Turoctocog alfa pegol	Turoctocog alfa pegol is indicated for use in adults and children with hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to...
Polymyxin B	A polymyxin antibiotic used to treat a wide variety of infections in the body.
Girentuximab	调查/治疗胆囊可以使用cer and renal cell carcinoma.
Risankizumab	An interleukin-23 antagonist used to treat moderate to severe plaque psoriasis, active psoriatic arthritis, and moderately to severely active Crohn's disease in adults.
Anetumab ravtansine	Anetumab ravtansine is under investigation in clinical trial NCT03455556 (Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung Cancer).
Isatuximab	A chimeric monoclonal antibody targeted against surface CD38 glycoproteins for the treatment of multiple myeloma in patients who have failed previous therapies.
Icrucumab	Icrucumab is under investigation in clinical trial NCT01111604 (A Study of IMC-1121B or IMC-18F1 in Colorectal Cancer).
Lintuzumab	Lintuzumab is under investigation in clinical trial NCT00016159 (Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia).
Vobarilizumab	Vobarilizumab is under investigation in clinical trial NCT02101073 (ALX-0061 Phase I Bioavailability Study in Healthy Volunteers).
Emactuzumab	Emactuzumab is under investigation in clinical trial NCT01494688 (A Study of RO5509554 as Monotherapy and in Combination With Paclitaxel in Participants With Advanced Solid Tumors).
Bevacizumab zirconium Zr-89	Bevacizumab zirconium Zr-89 is under investigation in clinical trial NCT01338090 (89Zr-bevacizumab PET Imaging in Patients With Neuroendocrine Tumors).
Refanezumab	Refanezumab is under investigation in clinical trial NCT00833989 (Safety Escalating Repeat IV, in Stroke Patients).
Pamrevlumab	Pamrevlumab is under investigation in clinical trial NCT00913393 (Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi and/or ARB Therapy).
Dalantercept	Dalantercept is under investigation in clinical trial NCT00996957 (Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma).
Pateclizumab	Pateclizumab is under investigation in clinical trial NCT01225393 (A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in...
Human interferon beta	A polypeptide drug used in the treatment of relapsing forms of Multiple Sclerosis (MS).
Apomab	Apomab is under investigation in clinical trial NCT00851136 (A Study of PRO95780 Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, and...
Ipafricept	Ipafricept is under investigation in clinical trial NCT01608867 (A Dose Escalation Study of OMP-54F28 in Subjects With Solid Tumors).
Abrilumab	Abrilumab is under investigation in clinical trial NCT01290042 (Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.).
Tigatuzumab	Tigatuzumab is under investigation in clinical trial NCT00991796 (CS-1008 With Carboplatin/Paclitaxel in Chemotherapy naïve Subjects With Metastatic or Unresectable Non-small Cell Lung Cancer (NSCLC)).
Utomilumab	Utomilumab is under investigation in clinical trial NCT03318900 (T Cell Immunotherapy for Advanced Ovarian Cancer).
Zolbetuximab	Zolbetuximab is under investigation in clinical trial NCT01630083 (Efficacy and Safety of IMAB362 in Combination With the EOX Regimen for CLDN18.2-positive Gastric Cancer).
Ponezumab	Ponezumab is under investigation in clinical trial NCT00607308 (A Phase I, Single Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease).
Asunercept	Asunercept is under investigation in clinical trial NCT02853565 (A Study of CAN008 for Newly Diagnosed Glioblastoma Multiforme).
Suvratoxumab	Suvratoxumab is under investigation in clinical trial NCT02296320 (Study of the Efficacy and Safety of MEDI4893).
Mitazalimab	Mitazalimab is under investigation in clinical trial NCT02379741 (ADC-1013 First-in-Human Study).
Bleselumab	Bleselumab is under investigation in clinical trial NCT02921789 (Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant...
Valanafusp alfa	Valanafusp alfa is under investigation in clinical trial NCT03071341 (Extension Study Evaluating Long Term Safety and Activity of AGT-181 in Children With MPS I).
Istiratumab	Istiratumab is under investigation in clinical trial NCT02399137 (A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer).
Pidilizumab	Pidilizumab is under investigation in clinical trial NCT01952769 (Anti PD1 Antibody in Diffuse Intrinsic Pontine Glioma).
GMA-161	GMA-161 is under investigation in clinical trial NCT00244257 (Safety Study of GMA161 in Patients With Idiopathic Thrombocytopenic Purpura (ITP)).
Tucotuzumab celmoleukin	Tucotuzumab celmoleukin is under investigation in clinical trial NCT00016237 (Interleukin-2 Combined With Monoclonal Antibody Therapy in Treating Patients With Kidney, Bladder, or Lung Cancer That Has Not Responded to Previous...
Ladiratuzumab vedotin	Ladiratuzumab vedotin is under investigation in clinical trial NCT01969643 (A Safety Study of SGN-LIV1A in Breast Cancer Patients).
Tomaralimab	Tomaralimab is under investigation in clinical trial NCT01794663 (Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function).
Vesencumab	Vesencumab is under investigation in clinical trial NCT00747734 (A Study of MNRP1685A in Patients With Locally Advanced or Metastatic Solid Tumors).
Pinatuzumab vedotin	Pinatuzumab vedotin is under investigation in clinical trial NCT01691898 (A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With...
Lulizumab pegol	Lulizumab pegol正在调查在临床中trial NCT02843659 (Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome).
Lorukafusp alfa	Lorukafusp alfa is under investigation in clinical trial NCT01334515 (Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma).
Naratuximab emtansine	Naratuximab emtansine is under investigation in clinical trial NCT01534715 (IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia).
CT-011	Investigated for use/treatment in cancer/tumors (unspecified).
Sonepcizumab	Investigated for use/treatment in solid tumors.
Thrombin alfa	A platelet activating factor used to treat minor bleeding.
Ravulizumab	A monoclonal antibody used to treat paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis.
Eftrenonacog alfa	A recombinant Factor IX used to treat and prevent bleeding in hemophilia B.
Depatuxizumab mafodotin	No approved indication.
Ublituximab	A low-fucose monoclonal anti-CD20 antibody with enhanced ADCC being investigated for use in leukemia, lymphoma, and autoimmune conditions such as multiple sclerosis.
Vadastuximab talirine	Vadastuximab Talirine has been used in trials studying the treatment of Acute myeloid leukemia, Myelodysplastic Syndrome, Acute Myelogenous Leukemia, and Acute Promyelocytic Leukemia.
Varlilumab	Varlilumab has been used in trials studying the treatment of MELANOMA, Skin Ulcer, Burkett's Lymphoma, Mantle cell lymphoma, and Any T-cell Malignancy, among others.
Urelumab	Urelumab has been used in trials studying the treatment of Leukemia, Multiple Myeloma, Malignant Tumors, and Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma. Urelumab is a fully human antibody...
Simtuzumab	Simtuzumab has been used in trials studying the treatment and basic science of Myelofibrosis, Pancreatic Cancer, Colorectal Cancer, and Idiopathic Pulmonary Fibrosis.
Fasinumab	A monoclonal antibody targeting nerve growth factor which is under investigation for the treatment of chronic cancer and non-cancer pain.
Luspatercept	An erythroid maturation agent used to treat anemia secondary to beta thalassemia in patients requiring regular red blood cell transfusions.
GS-5745	GS-5745 has been used in trials studying the treatment of Tumors, Breast Cancer, Crohn's Disease, Colorectal Cancer, and Pancreatic Cancer, among others.
Vanucizumab	Vanucizumab has been used in trials studying the treatment of ColoRectal Cancer and Advanced/Metastatic Solid Tumors.
Labetuzumab govitecan	Labetuzumab govitecan has been used in trials studying the treatment of Colon Cancer, Rectal Cancer, and Metastatic Colorectal Cancer.
Ensituximab	Ensituximab has been used in trials studying the treatment of Pancreatic Cancer, Adult, Metastatic Colorectal Cancer, and Metastatic Pancreatic Cancer.
Fezakinumab	Fezakinumab has been used in trials studying the treatment of Atopic Dermatitis and Rheumatoid Arthritis.
Indusatumab vedotin	我Indusatumab vedotin被用于试验ng the treatment of Pancreatic Adenocarcinoma, Adenocarcinoma of the Stomach, Recurrent Gastric Adenocarcinoma, Metastatic Gastric Adenocarcinoma, and Advanced Gastrointestinal Carcinoma, among others.
Lumretuzumab	Lumretuzumab has been used in trials studying the treatment of Neoplasms, Breast Cancer, Squamous Non-Small Cell Lung Cancer, and Non-Squamous Non-Small Cell Lung Cancer.
Ecromeximab	Ecromeximab has been used in trials studying the treatment of Cutaneous Melanoma and Metastatic Melanoma.
Pegvaliase	An enzyme used to treat phenylketonuria in patients with phenylalanine levels that are too high on current treatment.
Bimekizumab	An anti-IL-17A, IL-17F, and IL-17AF monoclonal antibody used in the treatment plaque psoriasis.
Rovalpituzumab tesirine	Rovalpituzumab Tesirine has been used in trials studying the treatment of GLIOBLASTOMA, Malignant Melanoma, Other Solid Tumors, Small Cell Lung Cancer, and Medullary Thyroid Cancer, among others.
Namilumab	Namilumab被用于试验研究ing the treatment of Plaque Psoriasis and Rheumatoid Arthritis.
Tregalizumab	Tregalizumab has been used in trials studying the treatment of Rheumatoid Arthritis.
Bezlotoxumab	A monoclonal antibody used to reduce the recurrence of Clostridium difficile infections.
Tisagenlecleucel	A CAR T cell therapy for relapsed or refractory large B-cell lymphoma and diffuse large B-cell lymphoma.
Burosumab	A fibroblast growth factor 23 blocking antibody used to treat X-linked hypophosphatemia.
Eptinezumab	A monoclonal antibody directed against CGRP infused every 3 months for the preventive treatment of migraine in adults.
Galcanezumab	A calcitonin-gene related peptide antagonist used to prevent migraines and treat cluster headaches.
Lecanemab	Lecanemab is an experimental drug that is currently in clinical trials for the treament of Alzheimer's disease.
Cemiplimab	A programmed death receptor-1 blocking antibody used to treat metastatic cutaneous squamous cell carcinoma.
Tagraxofusp	A CD123-directed cytotoxin used to treat plasmacytoid dendritic cell neoplasm.
Camrelizumab	Camrelizumab is under investigation in clinical trial NCT03417895 (SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy).
Setrusumab	Setrusumab is under investigation in clinical trial NCT01406548 (Safety and Efficacy of Multiple Dosing Regimens of BPS804 in Post Menopausal Women With Low Bone Mineral Density).
Gancotamab	Gancotamab is under investigation in clinical trial NCT02213744 (MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients).
Codrituzumab	Codrituzumab is under investigation in clinical trial NCT01507168 (A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma).
Brolucizumab	An anti VEGF-A monoclonal antibody indicated to treat neovascular age related macular degeneration.
Xentuzumab	Xentuzumab is under investigation in clinical trial NCT02191891 (Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)).
Parsatuzumab	Parsatuzumab is under investigation in clinical trial NCT01366131 (Study Evaluating the Safety and Efficacy of MEGF0444A in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced or Recurrent Non-Squamous...
Rozanolixizumab	Rozanolixizumab is under investigation in clinical trial NCT03861481 (A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy).
Opicinumab	Opicinumab is under investigation in clinical trial NCT02641041 (Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of BIIB033 in Healthy Japanese Participants).
Trastuzumab deruxtecan	An antibody used to treat certain types of unresectable or metastatic HER-2 positive breast cancer.
Margetuximab	An Fc-engineered human/mouse chimeric IgG1κ anti-HER2 monoclonal antibody indicated for patients with HER2-positive metastatic breast cancer.
Gremubamab	Gremubamab is under investigation in clinical trial NCT02255760 (Phase 1 Randomized Double-blind Placebo Controlled Study to Evaluate Safety and PK of MEDI3902 in Healthy Adults).
Tafasitamab	A CD19-directed cytolytic monoclonal antibody used in the treatment of B-cell malignancies.
Frovocimab	Frovocimab is under investigation in clinical trial NCT01671085 (A Study of LY3015014 in Healthy Participants With High Cholesterol).
Tezepelumab	A human monoclonal IgG2λ thymic stromal lymphopoietin (TSLP)-blocking antibody for add-on maintenance therapy in severe asthma.
Telisotuzumab vedotin	Telisotuzumab vedotin is under investigation in clinical trial NCT02099058 (A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Subjects With Advanced Solid Tumors.).
Nemolizumab	Nemolizumab is under investigation in clinical trial NCT03921411 (A Pharmacokinetics and Safety Study of Nemolizumab in Adolescent Subjects With Atopic Dermatitis (AD)).
Gedivumab	在临床试验Gedivumab正在调查中NCT01877785 (A Study of MHAA4549A to Assess Safety And Pharmacokinetics in Healthy Volunteers).
Sofituzumab vedotin	Sofituzumab vedotin is under investigation in clinical trial NCT01335958 (Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer).
Evinacumab	单克隆抗体针对angiopoetin-like protein 3 (ANGPTL3) used as an adjunct with other lipid-lowering therapies for the treatment of homozygous familiar hypercholesterolemia.
Zenocutuzumab	Zenocutuzumab is under investigation in clinical trial NCT03321981 (MCLA-128 With Trastuzumab/chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer).
Inolimomab	Inolimomab is under investigation as an agent to treat steroid-resistant graft vs host disease. It has thus far offered similar efficacy to other monoclonal antibody options, though it may carry...
Theralizumab	Theralizumab is a humanized anti-CD28 monoclonal antibody designed for treating autoimmune diseases and cancer. After the first human trial, it was withdrawn due to severe toxicity (likely due to lymphopenia...
Belantamab mafodotin	An anti B-cell maturation antigen antibody conjugated to a microtubule inhibitor to treat relapsed or refractory multiple myeloma.
Pentaglobin	Pentaglobin, also known as IgM-enriched immunoglobulin, falls under a group of polyclonal immunoglobulin preparations. It is comprised of immunoglobulin G (IgG) (https://www.drugbank.ca/drugs/DB00028) and immunoglobulin A (IgA) while also being enriched...
Agalsidase alfa	A recombinant human alpha-galactosidase indicated to treat Fabry disease, a genetic deficiency in the enzyme leading to buildup of globotriaosylceramide.
Abagovomab	Abagovomab is under investigation in clinical trial NCT00418574 (Efficacy Multicentre Trial of Immunotherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients).
Dapirolizumab pegol	Dapirolizumab pegol is under investigation in clinical trial NCT02804763 (A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus).
Efungumab	Efungumab is under investigation in clinical trial NCT00217815 (Preliminary Study of Mycograb and Docetaxel in Advanced Breast Cancer).
Foralumab	Foralumab is under investigation in clinical trial NCT03291249 (Assessment of the Safety of Foralumab, an Oral Anti-cd3 Antibody, in Patients With NASH and T2DM).
Indatuximab ravtansine	Indatuximab ravtansine is under investigation in clinical trial NCT01001442 (Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma).
Itolizumab	Itolizumab is under investigation in clinical trial NCT04605926 (A Study to Evaluate the Efficacy and Safety of Itolizumab in Subjects Hospitalized With COVID-19).
Magrolimab	Magrolimab is under investigation in clinical trial NCT02953782 (Trial of Magrolimab (Hu5f9-g4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer).
Olinvacimab	Olinvacimab is under investigation in clinical trial NCT03033524 (Trial to Evaluate the Safety of Ttac-0001(tanibirumab) in Recurrent Glioblastoma).
Ontuxizumab	Ontuxizumab is under investigation in clinical trial NCT01574716 (Sarcoma Study of Morab-004 Utilization: Research and Clinical Evaluation).
Otlertuzumab	Otlertuzumab is under investigation in clinical trial NCT01188681 (Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic Leukemia).
Anti-SARS-CoV-2 immunoglobulin	Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG) is obtained from the plasma of patients who recover from COVID-19 and develop neutralizing antibodies. Anti-coronavirus immunoglobulin is derived from COVID-19 convalescent plasma(//www.hxgjch.com/drugs/DB15692) but contains...
Silver proteinate	A nasal decongestant and antiseptic of the nasal and ear canals.
Actoxumab	Actoxumab is under investigation in clinical trial NCT01241552 (A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)).
Toralizumab	Toralizumab is under investigation in clinical trial NCT03605927 (CD40-L Blockade for Prevention of Acute Graft-versus-host Disease).
Birtamimab	Birtamimab is under investigation in clinical trial NCT02312206 (The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis).
Volagidemab	Volagidemab is under investigation in clinical trial NCT03117998 (Multiple Dose Study to Evaluate the Efficacy, Safety and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus).
Fibrin	Not Annotated
Antilymphocyte immunoglobulin (horse)	A primarily IgG immune globulin used to manage allograft rejection in renal transplant patients.
Tetanus immune globulin, human	A solution of antibodies used to prevent tetanus after an injury.
Digoxin Immune Fab (Ovine)	An antibody binding fragment which binds digoxin molecules which is used as an antidote to digoxin overdose.
Anthrax immune globulin human	An immunizing agent used for the treatment of inhalational anthrax in adult and pediatric patients in combination with antibacterial agents.
Bermekimab	Bermekimab is under investigation in clinical trial NCT01384630 (Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis).
Crizanlizumab	A monoclonal antibody that targets selectin to reduce the frequency of vasooclusive crises in patients with sickle cell disease.
Enfortumab vedotin	An antibody-drug conjugate comprised of a fully human monoclonal antibody and microtubule-disrupting chemotherapeutic agent used in the treatment of advanced or metastatic urothelial cancer.
Satralizumab	A subcutaneously injected anti-IL-6 receptor monoclonal antibody for the treatment of neuromyelitis optica spectrum disorder (NMOSD).
Odesivimab	Part of a product containing three monoclonal IgG1κ antibodies directed against the GP1,2 glycoprotein of Zaire ebolavirus. Together, these three antibodies act to neutralize viral particles and to recruit immune effectors for the destruction of both viral particles and infected cells.
Maftivimab	Part of a product containing three monoclonal IgG1κ antibodies directed against the GP1,2 glycoprotein of Zaire ebolavirus. Together, these three antibodies act to neutralize viral particles and to recruit immune effectors for the destruction of both viral particles and infected cells.
Atoltivimab	Part of a product containing three monoclonal IgG1κ antibodies directed against the GP1,2 glycoprotein of Zaire ebolavirus. Together, these three antibodies act to neutralize viral particles and to recruit immune effectors for the destruction of both viral particles and infected cells.
Bamlanivimab	A neutralizing human IgG1κ monoclonal antibody against the SARS-CoV-2 spike (S) protein for use in patients aged 12 and over at high risk of developing severe COVID-19.
Naxitamab	A GD2-targeted IgG1 monoclonal antibody for the treatment of high-risk relapsed/refractory neuroblastoma of the bone or bone marrow.
Ansuvimab	A fully human monoclonal IgG1 antibody directed against the GP1,2 surface protein of Zaire ebolavirus that is an effective treatment for Ebola virus disease.
Human Rho(D) immune globulin	A solution of antibodies used to prevent isoimmunization of Rho(D) negative patients exposed to Rho(D) positive blood in pregnancy or transfusion.
Bentracimab	Bentracimab is under investigation in clinical trial NCT04286438 (Bentracimab (PB2452) in Ticagrelor-treated Patients With Uncontrolled Major or Life-threatening Bleeding or Requiring Urgent Surgery or Invasive Procedure).
Cantuzumab ravtansine	Investigated for use/treatment in gastric cancer.
Cergutuzumab amunaleukin	Cergutuzumab amunaleukin is under investigation in clinical trial NCT02004106 (A Study to Evaluate Safety, Pharmacokinetics, and Efficacy of RO6895882 in Participants With Advanced and/or Metastatic Solid Tumors).
Gosuranemab	Gosuranemab is under investigation in clinical trial NCT02460094 (Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy).
Lifastuzumab vedotin	Lifastuzumab vedotin is under investigation in clinical trial NCT01363947 (Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Participants With Non-Small Cell Lung Cancer (NSCLC) and Platinum Resistant Ovarian Cancer).
Trastuzumab duocarmazine	Trastuzumab duocarmazine is under investigation in clinical trial NCT03262935 (SYD985 vs. Physician's Choice in Participants With Her2-positive Locally Advanced or Metastatic Breast Cancer).
Vorsetuzumab mafodotin	在c Vorsetuzumab mafodotin正在调查中linical trial NCT01677390 (A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma).
Anrukinzumab	Anrukinzumab has been used in trials studying the diagnostic of Asthma.
Bemarituzumab	Bemarituzumab is under investigation in clinical trial NCT03694522 (A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (Mfolfox6) in Gastric/gastroesophageal Junction Cancer (FIGHT)).
Brontictuzumab	Brontictuzumab has been used in trials studying the treatment of Adenoid Cystic Carcinoma, Relapsed or Refractory Solid Tumors, and Relapsed or Refractory Lymphoid Malignancies.
Cabiralizumab	Cabiralizumab is under investigation in clinical trial NCT03502330 (APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma).
Cusatuzumab	A CD70-directed monoclonal antibody under investigation for the treatment of hematological malignancies.
Dezamizumab	Dezamizumab is under investigation in clinical trial NCT03417830 (Biodistribution of 89Zirconium-labelled GSK2398852 Using PET Imaging).
Domagrozumab	Domagrozumab is under investigation in clinical trial NCT01616277 (A Phase 1 Study To Evaluate The Safety And Tolerability Of PF-06252616 In Healthy Subjects).
Dostarlimab	An anti-PD-1 monoclonal antibody used in the treatment of mismatch repair deficient endometrial cancers.
Enoblituzumab	Enoblituzumab is under investigation in clinical trial NCT02982941 (Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors).
Faricimab	An IgG1-derived bispecific antibody against VEGF-A and Ang-2 for the treatment of age-related macular degeneration and diabetic macular edema.
Flotetuzumab	Flotetuzumab is under investigation in clinical trial NCT02152956 (Safety Study of MGD006 in Relapsed/Refractory Acute Myeloid Leukemia (AML) or Intermediate-2/High Risk MDS).
Imgatuzumab	Imgatuzumab is under investigation in clinical trial NCT01326000 (A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With...
Lacnotuzumab	Lacnotuzumab is under investigation in clinical trial NCT01643850 (MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS)).
Lutikizumab	Lutikizumab is under investigation in clinical trial NCT02087904 (A Study Evaluating the Safety, Efficacy, and Pharmacodynamic Effects of ABT-981 in Patients With Knee Osteoarthritis).
Mirikizumab	Mirikizumab is under investigation in clinical trial NCT03053622 (A Study of Mirikizumab (LY3074828) Injection in Healthy Participants).
Monalizumab	Monalizumab has been used in trials studying the treatment of Gynecologic Cancer, Chronic Lymphocytic Leukemia, and Squamous Cell Carcinoma of the Oral Cavity.
Mosunetuzumab	A humanized anti-CD20/CD3 bispecific antibody used to treat relapsed or refractory follicular lymphoma.
Olendalizumab	Olendalizumab is under investigation in clinical trial NCT01883544 (Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALXN1007 in Healthy Male and Female Subjects).
Ozoralizumab	Ozoralizumab has been used in trials studying the treatment of Rheumatoid Arthritis and Active Rheumatoid Arthritis.
Pascolizumab	Investigated for use/treatment in asthma.
Vonlerolizumab	Vonlerolizumab is under investigation in clinical trial NCT03029832 (A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who...
Prasinezumab	Prasinezumab is under investigation in clinical trial NCT03100149 (A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease).
Quilizumab	Quilizumab is under investigation in clinical trial NCT01160861 (A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MEMP1972A in Patients With Allergic Rhinitis).
Ravagalimab	Ravagalimab is under investigation in clinical trial NCT03695185 (A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe It Is in Participants With Moderate to Severe Ulcerative Colitis...
Ruplizumab	Investigated for use/treatment in thrombocytopenia, systemic lupus erythematosus, transplant (rejection), blood (blood forming organ disorders, unspecified), and multiple sclerosis.
Samalizumab	Samalizumab has been used in trials studying the treatment of Multiple Myeloma and B-cell Chronic Lymphocytic Leukemia.
Spartalizumab	Spartalizumab is under investigation in clinical trial NCT02605967 (Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma).
Talacotuzumab	Talacotuzumab is under investigation in clinical trial NCT01632852 (A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission).
Tefibazumab	Tefibazumab is under investigation in clinical trial NCT00198289 (Aurexis® in Cystic Fibrosis Subjects Chronically Colonized With Staphylococcus Aureus in Their Lungs).
Telisotuzumab	Telisotuzumab is under investigation in clinical trial NCT01472016 (Study of ABT-700 in Subjects With Advanced Solid Tumors).
Tibulizumab	Tibulizumab is under investigation in clinical trial NCT03736772 (A Study of LY3090106 in Japanese and Caucasian Healthy Participants).
Tislelizumab	Tislelizumab is under investigation in clinical trial NCT02660034 (The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Subjects With Advanced Solid Tumors).
Tomuzotuximab	Tomuzotuximab is under investigation in clinical trial NCT02052960 (CetuGEX™ in Comparison to Cetuximab for the Treatment of Patients With Head and Neck Cancer).
Vatelizumab	Vatelizumab has been used in trials studying the treatment of Ulcerative Colitis.
Vopratelimab	Vopratelimab is under investigation in clinical trial NCT02904226 (JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors).
Vunakizumab	Vunakizumab is under investigation in clinical trial NCT03463187 (Multi-Dose Study of SHR-1314 in Subjects With Moderate-to-severe Plaque Psoriasis).
Amivantamab	An EGF and MET receptor targeted antibody indicated in the treatment of non-small cell lung cancer with an EGFR 20 exon insertion mutation.
Plasminogen	Plasma-derived human plasminogen administered intravenously to treat type 1 plasminogen deficiency (hypoplasminogenemia).
Sotrovimab	A monoclonal antibody for the treatment of mild-to-moderate COVID-19 in patients at increased risk for death or hospitalization.
Regdanvimab	A monoclonal antibody targeted against the SARS-CoV-2 spike protein used to treat patients with COVID-19 who are at risk of progressing to severe COVID-19.
Imdevimab	Part of an investigational recombinant monoclonal antibody cocktail used to treat mild to moderate COVID-19.
Casirivimab	Part of an investigational recombinant monoclonal antibody cocktail used to treat mild to moderate COVID-19.
Cilgavimab	An extended half-life recombinant monoclonal IgG1κ antibody directed against the SARS-CoV-2 S protein for COVID-19 prophylaxis in individuals unable to undergo COVID-19 immunization.
Tixagevimab	An extended half-life recombinant monoclonal IgG1κ antibody directed against the SARS-CoV-2 S protein for COVID-19 prophylaxis in individuals unable to undergo COVID-19 immunization.
Protein hydrolysate	Not Annotated
Ordesekimab	Ordesekimab is under investigation in clinical trial NCT02633020 (Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Type II Refractory Celiac Disease).
Cetrorelix	A synthetic peptide antagonist of gonadotropin releasing hormone used to prevent luteinizing hormone surges in women undergoing assisted reproduction therapy.
Citrulline	Used for nutritional supplementation, also for treating dietary shortage or imbalance.
Perflutren	A diagnostic medication to improve contrast during echocardiograms.
Gonadorelin	A synthetic GnRH used to test the function of gonadotropes and the pituitary.
Lucinactant	Intended for the prevention of respiratory distress syndrome (RDS) in premature infants at high risk for RDS.
REV131	Investigated for use/treatment in allergic reaction, allergic rhinitis, and cataracts.
CR665	Investigated for use/treatment in pain (acute or chronic).
Albinterferon Alfa-2B	Investigated for use/treatment in hepatitis (viral, C).
LJP 1082	Investigated for use/treatment in autoimmune diseases, strokes, and thrombosis.
Contulakin-G	Investigated for use/treatment in pain (acute or chronic).
Icatibant	A bradykinin B2 receptor antagonist used to treat acute episodes of swelling and inflammation associated with hereditary angioedema (HAE).
Labradimil	Investigated for use/treatment in brain cancer and pediatric indications.
TG4010	Investigated for use/treatment in breast cancer, renal cell carcinoma, prostate cancer, and lung cancer.
Buserelin	A LHRH agonist used for the palliative treatment of hormone-dependent advanced carcinoma of the prostate gland in males and treatment of endometriosis in females.
Ganirelix	A GnRH antagonist used in assisted reproduction in women undergoing controlled ovarian hyperstimulation to control ovulation by inhibiting the premature LH surges.
Histrelin	A GnRH agonist found in subcutaneous implants used for the treatment of pediatric patients with central precocious puberty and the palliative treatment of advanced prostate cancer.
Vonapanitase	Vonapanitase is under investigation for the treatment of Chronic Kidney Disease.
Bombesin	Bombesin is under investigation in clinical trial NCT01205321 (PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability and Diagnostic Performance of BAY86-7548 in Patients With Prostate Cancer and...
Ulinastatin	Ulinastatin has been investigated for the prevention of Cardiovascular Disease and Adverse Reaction to Drug.
Bradykinin	Bradykinin has been investigated for the basic science and treatment of Hypertension and Diabetes Type 2.
Selepressin	Selepressin has been used in trials studying the treatment of Septic Shock.
Tecemotide	Tecemotide has been used in trials studying the treatment of Prostate Cancer and Carcinoma, Non-Small-Cell Lung.
Aviscumine	Cy 503 is under investigation in clinical trial NCT00658437 (Aviscumine for the Treatment of Malignant Melanoma Stage IV After Failure of Prior Therapy).
Zoptarelin doxorubicin	Zoptarelin doxorubicin has been used in trials studying the treatment of Breast Cancer, Ovarian Cancer, Prostate Cancer, Endometrial Cancer, and Urothelial Carcinoma, among others.
Plasma protein fraction (human)	A plasma protein solution used to treat coagulation factor deficiencies, reverse anticoagulant effects, and shock from a loss of plasma fluids, and is also used in plasma exchange procedures.
PRM-151	PRM-151 is under investigation in clinical trial NCT01981850 (A Phase 2 Study Of PRM-151 In Subjects With Myelofibrosis).
Eflapegrastim	A form of recombinant human granulocyte colony stimulating factor used to induce the production of granulocytes and lower infection risk after myelosuppressive therapy.
Remtolumab	Remtolumab is under investigation in clinical trial NCT02433340 (Phase 2, Multicenter, Open-Label Extension (OLE) Study With ABT-122 in Rheumatoid Arthritis Subjects Who Have Completed the Preceding M12-963 Study).
Hemoglobin	An iron-containing protein found in all red blood cells (RBCs) for proper binding of oxygen and transport throughout the body, included in blood transfusions in severe hemorrhage.
Protein S human	A medication used for emergency reversal of coagulation factor deficiency in vitamin K antagonist therapy.
Fibronectin	Fibronectin is under investigation in clinical trial NCT01812239 (Vaginal Progesterone in Twins With Short Cervix).
Anistreplase	A form of recombinant human tissue plasminogen activator used in the emergency treatment of myocardial infarction and pulmonary emboli.
Tenecteplase	A modified form of recombinant human tissue plasminogen activator used in the emergency treatment of myocardial infarction and pulmonary emboli.
Interferon alfa-2a	A form of recombinant human interferon used to stimulate the innate antiviral response in the treatment of hepatitis B and C viruses.
Oprelvekin	A form of recombinant interleukin-11 used to stimulate production of megakaryocytes and platelets in patients with or at risk of thrombocytopenia after chemotherapy.
Drotrecogin alfa	A form of recombinant activated human protein C used to reduce mortality in patients with severe sepsis by inhibiting coagulation Factors V and VIII.
Interferon beta-1a	A form of recombinant human interferon used to slow disease progression and reduce the frequency of clinical symptoms in patients who have relapsing multiple sclerosis.
Interferon alfacon-1	A recombinant interferon similar the interferon alfa subtype which is used to treat hepatitis C infections.
Streptokinase	A purified fibrinolytic bacterial protein used to breakdown thrombosis in myocardial infarction, pulmonary embolism, and venous thromboembolism.
Alefacept	A recombinant fusion protein that binds CD2 and is used treat moderate to severe plaque psoriasis.
Felypressin	For use as an alternative to adrenaline as a localising agent, provided that local ischaemia is not essential.
Interferon alfa-2b	重组人干扰素用于混乱关系的一种形式at hepatitis B and C infection, genital warts, hairy cell leukemia, follicular lymphoma, malignant melanoma, and AIDs-related Kaposi's sarcoma.
Nafarelin	A gonadotropin releasing hormone agonist used to treat central precocious puberty.
Colistin	A polymyxin antibiotic used to treat bacterial infections caused by susceptible Gram negative bacteria.
Aminolevulinic acid	A porphyrin precursor used to treat actinic keratosis of the face, scalp, and upper extremities, as well as to visualize a glioma.
Colistimethate	An antibiotic indicated for treatment of infections caused by susceptible strains of certain gram-negative bacilli. It is particularly useful for targeting sensitive strains of Pseudomonas aeruginosa.
Paclitaxel	A taxoid chemotherapeutic agent used as first-line and subsequent therapy for the treatment of advanced carcinoma of the ovary, and other various cancers including breast and lung cancer.
Pramlintide	An amylin analog used for the management of type 1 and type 2 diabetes mellitus as an adjunct to preprandial insulin therapy in patients without adequate glycemic control of insulin therapy.
Galsulfase	A recombinant human enzyme used as replacement enzyme therapy for the treatment of of adults and children with Mucopolysaccharidosis VI, a rare genetic disorder caused by a deficiency of a lysosomal enzyme.
Abatacept	A disease-modifying antirheumatic drug (DMARD) used in the management of rheumatic conditions, such as rheumatoid or psoriatic arthritis, and for the prophylaxis of acute graft-versus-host disease.
Tetracosactide	A diagnostic agent used in the screening of patients presumed to have adrenocortical insufficiency.
Corticotropin	A diagnostic agent used in the screening of patients presumed to have adrenocortical insufficiency.
Thyroglobulin	For the treatment of hypothyroidism (deficiency in the production of thyroid hormone).
Bacteriochlorophyll A	A specific bacteriochlorophyll that is similar in structure to CHLOROPHYLL A.
Terlipressin	A drug used to treat bleeding caused by esophageal varices.
Vapreotide	For the treatment of esophageal variceal bleeding in patients with cirrhotic liver disease and has also shown efficacy in the treatment of patients with AIDS-related diarrhea.
Nesiritide	A recombinant natriuretic peptide used for the treatment of patients with acutely decompensated congestive heart failure who have dyspnea at rest or with minimal activity.
Thymalfasin	Indicated as an adjuvant for influenza vaccine in elderly patients and as an adjuvant for both influenza and hepatitis B vaccines in chronic hemodialysis patients who failed to achieve adequate...
G17DT	Intended for the treatment of various forms of cancer.
Dirucotide	For the treatment of multiple sclerosis (MS).
Desmoteplase	Investigated for use/treatment in cerebral ischemia and strokes.
Tigapotide	For the treatment of late stage Hormone Refractory Prostate Cancer (HRPC) for which no effective therapy currently exists.
Abaloparatide	A parathyroid hormone-related protein (PTHrP) analog used for the treatment of osteoporosis in postmenopausal women with a high risk of fracture.
Leptin	Investigated for use/treatment in lipodystrophy and obesity.
Topsalysin	Investigated for use/treatment in benign prostatic hyperplasia, cancer/tumors (unspecified), prostate cancer, prostate disorders, and solid tumors.
Elafin	Investigated for use/treatment in inflammatory disorders (unspecified).
Interferon alfa	An immunomodulator used to treat hepatitis B and C as well as certain types of cancer including cutaneous T-cell lymphoma and renal cell carcinoma.
Glatiramer	An immunomodulator used to reduce the frequency of relapses in Multiple Sclerosis (MS).
Keyhole limpet hemocyanin	Investigated for use/treatment in bladder cancer and solid tumors.
Cintredekin besudotox	Investigated for use/treatment in brain cancer.
Romiplostim	A fusion protein thrombopoietin (TPO) peptide analog that increases platelet counts by binding to and activating the human TPO receptor. Used to treat thrombocytopenia associated with chronic immune thrombocytopenia (ITP).
Ciliary neurotrophic factor	Investigated for use/treatment in eye disorders/infections, macular degeneration, and retinal disorders (unspecified).
Regramostim	Investigated for use/treatment in adverse effects (chemotherapy) and bone marrow transplant.
Corticorelin	一种合成促肾上腺皮质激素的释放因子模拟used to diagnose causes of excessive adrenocorticotropic hormone (ACTH) production.
Tifuvirtide	Investigated for use/treatment in acquired immune deficiency syndrome (AIDS) and aids-related infections and HIV infection.
Talactoferrin alfa	Investigated for use/treatment in adverse effects (chemotherapy), cancer/tumors (unspecified), diabetic foot ulcers, lung cancer, solid tumors, and ulcers.
Praconase	Investigated for use/treatment in spinal cord injuries.
Fibroblast growth factor-1	Investigated for use/treatment in coronary artery disease and peripheral vascular disease.
IRX-2	Investigated for use/treatment in cancer/tumors (unspecified), head and neck cancer, and solid tumors.
Maxy-G34	Investigated for use/treatment in adverse effects (chemotherapy) and neutropenics.
Thrombomodulin Alfa	Investigated for use/treatment in blood preservative, blood (blood forming organ disorders, unspecified), sepsis and septicemia, and thrombosis.
Sar9, Met (O2)11-Substance P	Investigated for use/treatment in acute respiratory distress syndrome (ARDS) and viral infection.
Pegdinetanib	Investigated for use/treatment in cancer/tumors (unspecified) and macular degeneration.
CTCE-0214	Investigated for use/treatment in adverse effects (chemotherapy), blood (blood forming organ disorders, unspecified), cancer/tumors (unspecified), neutropenics, and vascular diseases.
GI-5005	Investigated for use/treatment in hepatitis (viral, C).
IRL-1620	Investigated for use/treatment in cancer/tumors (unspecified).
Nelipepimut-S	Investigated for use/treatment in prostate cancer and breast cancer.
Trafermin	Investigated for use/treatment in coronary artery disease, peripheral vascular disease, periodontal disease, bone fractures, entero-related fistulae, and diabetic foot ulcers.
Lanoteplase	调查/治疗心肌infar使用ction.
Aviptadil	Not Annotated
Otilimab	Investigated for use/treatment in inflammatory disorders (unspecified).
AZX-100	Investigated for use/treatment in scar tissue.
Rilonacept	An IL-1 inhibitor used to treat cryopyrin-associated periodic syndrome, a rare hereditary inflammatory disorder.
Calcitonin gene-related peptide	调查/治疗心肌infar使用ction, heart disease, and asthma.
Atacicept	Investigated for use/treatment in autoimmune diseases, systemic lupus erythematosus, rheumatoid arthritis, multiple myeloma, lymphoma (non-hodgkin's), and leukemia (lymphoid).
Vitespen	Investigated for use/treatment in kidney cancer, melanoma, renal cell carcinoma, lymphoma (unspecified), colorectal cancer, and brain cancer.
Endostatin	Investigated for use/treatment in cancer/tumors (unspecified), macular degeneration, and diabetic retinopathy.
Repifermin	Investigated for use/treatment in bone marrow transplant, ulcers, and inflammatory bowel disease.
Velafermin	Investigated for use/treatment in adverse effects (chemotherapy).
Onercept	Investigated for use/treatment in psoriasis and psoriatic disorders and crohn's disease.
AMGN-0007	Investigated for use/treatment in osteoporosis and bone metastases.
Thrombopoietin	Investigated for use/treatment in thrombocytopenia.
Atibuclimab	调查使用/治疗脓毒症和解剖cemia and pneumonia.
Emfilermin	Investigated for use/treatment in adverse effects (chemotherapy), reproductive health, and infertility.
Baminercept	Investigated for use/treatment in rheumatoid arthritis.
Omiganan	Investigated for use/treatment in bacterial infection and rosacea.
Pegsunercept	Investigated for use/treatment in rheumatoid arthritis.
DiaPep 277	Investigated for use/treatment in diabetes mellitus type 1, autoimmune diseases, and diabetes mellitus type 2.
Pasireotide	A somatostatin analog used in the treatment of Cushing’s disease, specifically for those patients whom pituitary surgery is not appropriate.
Amediplase	调查/治疗心肌infar使用ction and thrombosis.
Belatacept	A selective T-cell costimulation blocker used in the prophylaxis of organ rejection in adult patients receiving a kidney transplant.
Lanreotide	用于治疗生长激素抑制素模拟联合国resectable, well- or moderately-differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors and acromegaly.
Triptorelin	A GnRH agonist indicated for the palliative treatment of advanced prostate cancer.
DADLE	A delta-selective opioid (ANALGESICS, OPIOID). It can cause transient depression of mean arterial blood pressure and heart rate.
DPDPE	A heterodetic cyclic peptide that is a cyclic enkephalin analogue, having D-penicillaminyl residues located at positions 2 and 5, which form the heterocycle via a disulfide bond.
Tesamorelin	A growth hormone releasing factor (GRF) analog used to reduce excessive abdominal fat in HIV patients who have developed lipodystrophy.
Aflibercept	A vascular endothelial growth factor (VEGF) inhibitor used to treat Neovascular (Wet) Age-Related Macular Degeneration (AMD), various types of macular edema and diabetic retinopathy.
Glucarpidase	A carboxypeptidase enzyme used to reduce plasma concentrations of methotrexate in patients with impaired renal function.
Corticorelin ovine triflutate	A synthetic corticotropin-releasing hormone used for diagnostic purposes in differentiating pituitary and ectopic production of ACTH in patients with ACTH-dependent Cushing's syndrome.
Somatostatin	A natural peptide hormone used to treat acute bleeding from esophageal varices, gastrointestinal ulcers, and gastritis; prevent pancreatic complications after surgery; and restrict secretions of the upper intestine, pancreas, and biliary tract.
Ancestim	A human stem cell factor used in combination with filgrastim during autologous peripheral blood progenitor cell (PBPC) transplantation to increase PBPC mobilization for improved collection.
甲氧基聚乙烯glycol-epoetinβ	A synthetic erythropoiesis stimulating agent (ESA) used to treat anemia associated with chronic kidney disease.
Turoctocog alfa	An antihemorrhagic agent used for the treatment and prophylaxis of bleeding in patients of all ages with haemophilia A (congenital factor VIII deficiency).
Chorionic Gonadotropin (Human)	A naturally-occurring hormone produced during human placenta used for the treatment of prepubertal cryptorchidism and hypogonadotropic hypogonadism in selected males, and induction of pregnancy in selected infertile women.
Polaprezinc	Peptic ulcer disease, dyspepsia .
Fibrinogen human	A hemostatic agent used for the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.
Conestat alfa	A recombinant C1INH used for the treatment of acute attacks of hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency in adults.
Antihemophilic factor (recombinant), PEGylated	For the management of hemophilia A (congenital factor VIII deficiency) [FDA label], . This medication is a human antihemophilic factor indicated in adolescent and adult patients (12 years and older)...
Technetium Tc-99m nofetumomab merpentan	Tc-99m nm is one of the technetium-labeled antibodies and it is indicated for the detection of small-cell lung cancer. The small cell lung cancer is a syndrome characterized by the...
Gastric intrinsic factor	Intrinsic factor is not currently available in any FDA or Health Canada approved products. However, it is currently in the marketed (but unapproved) product Hematogen in combination with cyanocobalamin (synthetic...
Protirelin	A synthetic analogue of thyrotropin-releasing hormone that has been used during diagnostic tests to evaluate function of the thyroid gland.
Secretin human	A secretin hormone used to stimulate pancreatic or gastric secretions to diagnose exocrine pancreas dysfunction, gastrinoma, and abnormalities in the bile and pancreatic ducts.
Human papillomavirus type 16 L1 capsid protein antigen	Human papillomavirus type 16 L1 capsid protein antigen is contained in Gardasil, or a recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) vaccine for intramuscular injection. It is...
Bordetella pertussis pertactin antigen	Bordetella pertussis pertactin antigen is a vaccine for the prophylaxis of whooping cough that contains pertactin, a membrane-associated antigen of Bordetella pertussis .
Desirudin	Indicated as prophylaxis of deep vein thrombosis for patients undergoing hip replacement surgery.
Iron protein succinylate	Not Annotated
Gelatin	Gelatin is used for weight loss and for treating osteoarthritis, rheumatoid arthritis, and brittle bones (osteoporosis). Some people also use it for strengthening bones, joints, and fingernails. Gelatin is also...
Thrombin	A coagulation factor used to stop bleeding during surgery.
Prothrombin	A coagulation factor used for emergency reversal of vitamin K antagonist therapy.
Factor IX Complex (Human)	A Factor IX complex used to prevent and treat bleeding episodes in hemophilia B or vitamin K antagonist therapy.
Deslorelin	Deslorelin acetate is an injectable gonadotropin releasing hormone super-agonist also known as an LHRH agonist. It stops the production of sex hormones.
Epoetin delta	Epoetin Delta is an ingredient in the EMA-withdrawn product Dynepo.
Eptotermin alfa	A bone morphogenetic protein that is widely expressed during EMBRYONIC DEVELOPMENT. It is both a potent osteogenic factor and a specific regulator of nephrogenesis. Eptotermin alfa is an ingredient in...
Dibotermin alfa	indicated for the treatment of acute tibia fractures in adults, as an adjunct to standard care using open fracture reduction and intramedullary unreamed nail fixation [FDA Label]. indicated for single-level...
Rusalatide acetate	Chrysalin has been used in trials studying the treatment of Radius Fracture.
Carnosine	Carnosine has been investigated for the treatment of Gulf War Illness.
Angiotensin 1-7	TXA127 has been investigated for the treatment of Miscellaneous Peripheral Blood Cell Abnormalities.
Endostar	Endostar is under investigation for the treatment of Nasopharyngeal Carcinoma. Endostar has been investigated for the treatment of Non-small Cell Lung Cancer.
Neuropeptide Y	基本神经肽Y正在调查中c science of Type 2 Diabetes Mellitus.
Indium In-111 pentetreotide	Indium In 111 pentetreotide (Octreoscan) has been used in trials studying the diagnostic of SARCOIDOSIS, Solid Tumors, and cushing syndrome.
Angiotensin II	A peptide hormone of the RAAS system used to raise blood pressure in septic or other forms of shock.
Tesidolumab	Tesidolumab has been used in trials studying the treatment of Geographic Atrophy, Non-infectious Panuveitis, Exudative Macular Degeneration, Non-infectious Posterior Uveitis, and Age-related Macular Degeneration, among others.
Avotermin	Juvista has been investigated for the treatment, prevention, and basic science of Scars, Keloid, and Cicatrix.
TAK-448	TAK-448 has been used in trials studying the treatment of Prostate Cancer, Low Testosterone, Prostatic Neoplasms, and Hypogonadotropic Hypogonadism.
Interleukin-7	Interleukin 7 has been used in trials studying the treatment of Metastatic Breast Cancer.
Thymosin beta-4	Thymosin Beta 4 has been investigated for the treatment of STEMI, Dry Eye, Diabetes, Pressure Ulcers, and Dry Eye Syndrome, among others.
Ulocuplumab	Ulocuplumab is under investigation in Solid Tumor.
Trebananib	Trebananib is under investigation for the treatment of Ovarian Cancer, Peritoneal Cancer, and Fallopian Tube Cancer. Trebananib has been investigated for the treatment of Cancer, Oncology, Carcinoma, Metastases, and Colon...
Nagrestipen	Nagrestipen has been used in trials studying the treatment of CANCER, Neoplasm, Metastasis, Radiation Oncology, and Neoplasm Metastasis.
TT-232	Tln 232 is under investigation in clinical trial NCT00422786 (Phase II Study of CAP-232 in Patients With Refractory Metastatic Renal Cell Carcinoma).
Vanutide cridificar	Vanutide cridificar has been investigated for the treatment of Alzheimer Disease.
Binetrakin	Binetrakin has been used in trials studying the treatment of HIV Infections, Sarcoma, Kaposi, Non-Hodgkin's Lymphoma (NHL), Myelodysplastic Syndrome (MDS), and Leukemia, Acute Myelogenous (AML), among others.
Tetulomab tetraxetan Lu-177	Betalutin has been used in trials studying the treatment of Non-Hodgkin Lymphoma and Relapsed, Diffuse Large B-cell Lymphoma.
Abicipar Pegol	Abicipar Pegol has been used in trials studying the treatment of Macular Edema and Macular Degeneration.
Blisibimod	Blisibimod has been used in trials studying the treatment of IgA Nephropathy, Microscopic Polyangiitis, Systemic Lupus Erythematosus, and Granulomatosis With Polyangiitis.
Dulanermin	Dulanermin has been used in trials studying the treatment of Colorectal Cancer, Non-Hodgkin's Lymphoma, and Metastatic Colorectal Cancer.
Fletikumab	Fletikumab is under investigation in clinical trial NCT01038674 (Safety and Tolerability of Anti-IL-20 in Subjects With Rheumatoid Arthritis).
Vatreptacog alfa	Vatreptacog Alfa (Activated) has been used in trials studying the treatment of Haemophilia B, Haemophilia A, Congenital Bleeding Disorder, Haemophilia A With Inhibitors, and Haemophilia B With Inhibitors.
Muplestim	Muplestim is under investigation in clinical trial NCT00002258 (A Phase I, Open Label Trial to Evaluate the Safety, Tolerance and Biological Effects of SDZ ILE-964 (Recombinant Human Interleukin-3, RhIL-3) in...
Conbercept	Conbercept has been investigated for the basic science of Age-related Macular Degeneration.
Molgramostim	Molgramostim has been used in trials studying the treatment of Bronchiectasis, Cystic Fibrosis, Pulmonary Alveolar Proteinosis, Acute Respiratory Distress Syndrome, and Autoimmune Pulmonary Alveolar Proteinosis.
Pentetreotide	A somatostatin receptor inhibitor, available in a kit with Indium-111, used as a contrast agent in the visualization of somatostatin receptor-positive neuroendocrine tumours.
Sprifermin	Sprifermin has been used in trials studying the treatment of Osteoarthritis, Knee and Cartilage Injury of Knee.
Nerve Growth Factor	Nerve Growth Factor has been used in trials studying the prevention and treatment of Mental Handicap, Alzheimer's Disease, Traumatic Brain Injury, Cerebral Palsy Children, and Delayed Speech Development, among others.
Aclerastide	Aclerastide has been investigated for the treatment of Diabetic Foot, Diabetic Foot Ulcers, and Foot Ulcer, Diabetic.
Navicixizumab	Navicixizumab is under investigation in clinical trial NCT02298387 (A Phase 1 Study of Navicixizumab in Subjects With Solid Tumors).
Endothelin-1	Endothelin 1 is under investigation in clinical trial NCT00745693 (The Effects of Diesel Exhaust Inhalation on Vascular Function - the Role of Endothelin).
Balugrastim	Balugrastim has been used in trials studying the treatment of Solid Tumors.
Monteplase	Monteplase has been used in trials studying the treatment of Pulmonary Embolism.
Firategrast	Firategrast has been used in trials studying the treatment of Multiple Sclerosis.
Tiplimotide	Tiplimotide has been used in trials studying the treatment of Multiple Sclerosis.
Somatoprim	Somatoprim正在调查中应用t of Acromegaly.
Pancreatic Polypeptide	Pancreatic Polypeptide has been investigated for the treatment of Diabetes Mellitus, Type 1.
Olipudase alfa	A recombinant human acid sphingomyelinase used to treat Acid Sphingomyelinase Deficiency (ASMD) in children and adults.
Interleukin-10	Interleukin-10 has been used in trials studying the prevention and treatment of Vasculitis, Pancreatitis, Bile Duct Diseases, Pancreatic Diseases, and Gallbladder Diseases, among others.
Factor XIII (human)	A purified form of Factor XIII that is used to prevent and treat surgical bleeding in patients with a Factor XIII deficiency.
Isoxaflutole	Balance has been investigated for the treatment of Chronic Renal Failure and Peritoneal Membrane Disorder.
Albusomatropin	Albusomatropin has been used in trials studying the treatment of Growth Hormone-Deficiency and Growth Hormone Deficiency.
Von Willebrand factor human	A blood clotting factor used to manage bleeding episodes in von Willebrand disease and hemophilia A,.
Lenograstim	A granulocyte colony-stimulating factor indicated in the reduction of duration of neutropenia in bone marrow transplant and cytotoxic chemotherapy, as well as mobilizing hematopoietic stem cells in healthy donors.
Coagulation factor X human	A coagulation factor used to treat Factor X deficiency to control bleeding.
Coagulation factor VII human	A coagulation factor used to treat bleeding disorders such as hemophilia and Glanzmann's thrombasthenia.
Anti-inhibitor coagulant complex	A medication used to control bleeding episodes and prevent bleeding episodes in hemophilia A and B.
Coagulation Factor IX Human	A coagulation factor used to treat hemophilia B or factor IX hemophilia.
Cerliponase alfa	An enzyme replacement therapy used to treat neuronal ceroid lipofuscinosis type 2 (CLN2) disease, also known as tripeptidyl peptidase 1 (TPP1) deficiency.
Antihemophilic factor human	A Factor VIII replacement therapy used to treat hemophilia A.
Kallidinogenase	Not Annotated
Lipegfilgrastim	A medication used to reduce the duration of chemotherapy-induced neutropenia and incidence of febrile neutropenia in cytotoxic chemotherapy.
Trenonacog alfa	Human coagulation factor IX (EC 3.4.21.22, Christmas factor, plasma thromboplastin component), produced in CHO cells.
Alsactide	Not Annotated
Sulglicotide	Not Annotated
Ornipressin	Not Annotated
Saruplase	Not Annotated
Protamine	A heparin antagonist indicated in the treatment of heparin overdoses, to counteract heparins preoperatively, or during cardiac surgery and dialysis.
Elcatonin	Not Annotated
Hemoglobin crosfumaril	Hemoglobin in which the alpha-subunit are cross-linked intramolecularly.
Albutrepenonacog alfa	A recombinant Factor IX fused to recombinant human albumin used to treat hemophilia B.
Cenegermin	A recombinant human nerve growth factor used to treat neurotrophic keratitis.
Nonacog beta pegol	A recombinant coagulation Factor IX derivative used to treat hemophilia B.
Moroctocog alfa	A recombinant Factor VIII used to treat hemophilia A to control bleeding.
Interleukin-1 alpha, human recombinant	Not Annotated
Basic Fibroblast Growth Factor	Basic Fibroblast Growth Factor is not currently approved for any FDA or Health Canada approved indications.
Nepidermin	Not Annotated
Insulin-like growth factor II	胰岛素样生长因子II well-characterized neutral peptide believed to be secreted by the liver and to circulate in the blood. This factor presents effects related to growth...
Beroctocog alfa	Beroctocog alfa is indicated for the prevention and control of bleeding in patients with hemophilia A or acquired Factor VIII (FVIII) deficiency. It is also indicated for surgical/invasive procedures in...
Andexanet alfa	A recombinant Factor Xa used to reverse anticoagulation caused by rivaroxaban and apixaban.
Lypressin	Not Annotated
Prezatide copper	Commonly used in cosmetic products for the skin and hair .
Peginterferon lambda-1a	Peginterferon lambda-1a is under investigation in clinical trial NCT01754974 (Safety and Efficacy Study of Peginterferon Lambda-1a vs. Peginterferon Alfa-2a, Plus Ribavirin in Subjects With Genotype 1 Hepatitis C).
Vofatamab	Vofatamab is under investigation in clinical trial NCT02401542 (Dose Escalation, Expansion Study of Vofatamab (B-701) in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma).
Procalcitonin	Procalcitonin is under investigation in clinical trial NCT03440060 (Procalcitonin-guided Antibiotic Therapy During Severe Exacerbation of COPD).
Osocimab	Osocimab is under investigation in clinical trial NCT03276143 (Factor XIa inhibition for the prevention of venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty).
Human interleukin-2	Human interleukin-2 is under investigation in clinical trial NCT03475134 (TIL-ACT After NMA Chemo With IL-2 and Nivo Rescue in mMEL).
Uteroglobin	Uteroglobin is under investigation in clinical trial NCT01473264 (Safety, Pk and Anti-inflammatory Effects of CC10 Protein in Premature Infants With Respiratory Distress Syndrome (RDS)).
Selicrelumab	Selicrelumab is under investigation in clinical trial NCT01008527 (Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100).
Sutimlimab	A monoclonal antibody directed towards complement subunit C1s used to reduce the need for blood transfusion due to hemolysis in patients with cold agglutinin disease.
Recombinant CD40-ligand	Recombinant CD40-ligand is under investigation in clinical trial NCT00053391 (Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma).
Toripalimab	Toripalimab is under investigation in clinical trial NCT03919383 (Phase II of Lenvatinib Plus Toripalimab for Advanced HCC).
Melanoma antigen recognized by T-cells 1	Melanoma antigen recognized by T-cells 1 is under investigation in clinical trial NCT01748747 (Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery).
Anfibatide	Anfibatide is under investigation in clinical trial NCT01585259 (Anfibatide Phase Ib-IIa Clinical Trial).
Leridistim	Leridistim is under investigation in clinical trial NCT00004215 (Leridistim Compared With Filgrastim in Treating Older Patients With Acute Myeloid Leukemia).
Interferon alfa-2c	Interferon alfa-2c is under investigation in clinical trial NCT00485563 (A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma).
Bempegaldesleukin	Bempegaldesleukin is under investigation in clinical trial NCT03729245 (A Study of NKTR-214 in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib...
Lenzilumab	Lenzilumab is under investigation in clinical trial NCT02546284 (Study of Lenzilumab in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML)).
Pegilodecakin	Pegilodecakin is under investigation in clinical trial NCT03382912 (Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer).
Tirzepatide	A dual GIP and GLP-1 receptor agonist used for the treatment of type II diabetes in adults as an adjunct to diet and exercise.
alpha-Lactalbumin	alpha-Lactalbumin is under investigation in clinical trial NCT02082418 (Effects of Alpha-lactalbumin Intake on Metabolic and Cognitive Functions in Elderly).
Gastric inhibitory polypeptide	Gastric inhibitory polypeptide is under investigation in clinical trial NCT03081676 (The Effect of GIP and GLP-1 on Insulin and Glucagon Secretion in Patients With HNF1A-diabetes Treated With or Without Sulphonylurea).
Avidin	Avidin is under investigation in clinical trial NCT00345618 (Clinical Study Assessing Idrabiotaparinux Sodium Injections Once-weekly in Pulmonary Embolism Therapeutic Approach).
Iscalimab	Iscalimab is under investigation in clinical trial NCT03905525 (Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjögren's Syndrome).
Futuximab	Futuximab is under investigation in clinical trial NCT01955473 (Japanese Phase 1 Trial of Sym004 in Solid Tumors).
Edratide	Edratide is under investigation in clinical trial NCT00203151 (A Study to Evaluate the Tolerability, Safety and Effectiveness of Edratide in the Treatment of Lupus).
Marzeptacog alfa (activated)	Marzeptacog alfa (activated) is under investigation in clinical trial NCT01439971 (Phase 1 Safety, Pharmacokinetics And Pharmacodynamics Study Of Recombinant Factor VIIa Variant (813d) In Adult Subjects With Hemophilia).
Gimsilumab	Gimsilumab is under investigation in clinical trial NCT01357759 (Safety and Tolerability of MORAb-022 in Healthy and Rheumatoid Arthritis Subjects).
Tebentafusp	A bispecific gp100 peptide-HLA-directed CD3 T cell engager used to treat unresectable or metastatic uveal melanoma.
Ontamalimab	Ontamalimab is under investigation in clinical trial NCT03627091 (Efficacy and Safety Study of SHP647 as Maintenance Treatment in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 307)).
Bevifimod	Bevifimod is under investigation in clinical trial NCT01749787 (Safety Study of PRTX-100 With Methotrexate or Leflunomide to Treat Active Rheumatoid Arthritis).
Orilanolimab	Orilanolimab is under investigation in clinical trial NCT03075878 (A Safety Study of SYNT001 in Subjects With Chronic, Stable Warm Autoimmune Hemolytic Anemia (WAIHA)).
das - 181	das - 181is under investigation in clinical trial NCT00527865 (Single Dose Escalating Study of DAS181 in Adults).
Vocimagene amiretrorepvec	Vocimagene amiretrorepvec is under investigation in clinical trial NCT02576665 (A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca...
Pegbelfermin	Pegbelfermin is under investigation in clinical trial NCT03486899 (A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis).
SOR-C13	SOR-C13 is under investigation in clinical trial NCT01578564 (Safety and Tolerability Study of SOR-C13 in Subjects With Advanced Cancers Commonly Known to Express the TRPV6 Channel).
ALT-801	ALT-801 is under investigation in clinical trial NCT01478074 (ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia).
Teceleukin	Teceleukin is under investigation in clinical trial NCT03610490 (Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Osteosarcoma, or Pancreatic Ductal Adenocarcinoma).
Coagulation factor XIa	Coagulation factor XIa is under investigation in clinical trial NCT01701947 (HEMOLEVEN® Expanded Access Program Prevention of Surgical/Postpartum Hemorrhage Severe Inherited Factor XI Deficiency).
Elgemtumab	Elgemtumab is under investigation in clinical trial NCT02167854 (Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer).
Onasemnogene abeparvovec	A gene therapy used to treat neonatal and infant patients with spinal muscular atrophy caused by bi-allelic mutations in the survival motor neuron 1 (SMN1) gene.
Silk sericin	Not Annotated
Padeliporfin	A vascular-acting photosensitizer used to treat low-risk prostate cancer in adults.
Spesolimab	An interleukin-36 receptor antagonist used to treat generalized pustular psoriasis flares in adults.
Edodekin alfa	Edodekin alfa is under investigation in clinical trial NCT01468896 (Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That Is Recurrent, Metastatic, or...
Temelimab	Temelimab is under investigation in clinical trial NCT02782858 (Clinical Trial Assessing the HERV-W Env Antagonist Gnbac1 for Efficacy in MS).
Zilucoplan	Zilucoplan is under investigation in clinical trial NCT04225871 (Open-label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis).
现代化COVID -19 Vaccine	An mRNA vaccine for the prevention of COVID-19, the disease caused by the SARS-CoV-2 virus, in patients aged 18 years and older.
Anti-SARS-CoV-2 REGN-COV2	Anti-SARS-COV-2 REGN-COV2 is a combination of novel antibodies designed by Regeneron for both the prevention and treatment of SARS-COV-2, the virus that causes COVID-19. This drug is a combination of...
BNT162b1 SARS-CoV-2 Vaccine	BNT162b1 is one of four advanced mRNA-based vaccines being developed through "Project Lightspeed," a joint program between Pfizer and BioNTech.[L15002, L15007] BNT162b1 is a nucleoside modified mRNA (modRNA) vaccine encoding...
Pfizer-BioNTech COVID-19 Vaccine	An mRNA vaccine for the prevention of COVID-19, the disease caused by the SARS-CoV-2 virus.
Brexucabtagene autoleucel	A modified autologous chimeric antigen receptor (CAR) T cell therapy employing a modified murine anti-CD19 single-chain variable fragment linked to CD28 and CD3ζ co-stimulatory domains for the treatment of patients with relapsed and refractory mantle cell lymphoma.
Alunacedase alfa	Alunacedase alfa is a recombinant and soluble glycosylated form of human ACE2. This recombinant version of the enzyme has antihypertensive and potential antineoplastic activities.
Viral Macrophage-Inflammatory Protein	Viral macrophage inflammatory protein-II (vMIP) is a highly basic protein and human chemokine analog encoded by human herpesvirus-8. The structure of vMIP consists of 71 residues and is a monomer...
Interferon Kappa	Interferon kappa is a subclass of type I interferon mediating host defence which consists of 207 amino acids and has 30% homology with others of the same class as it...
Sintilimab	Not Annotated
Envafolimab	Not Annotated
AZD7442	AZD7442 is a combination of SARS-CoV-2 antibodies (AZD8895 + AZD1061) currently undergoing phase I clinical trials for the prevention and treatment of COVID-19. It was developed by AstraZeneca with the...
XAV-19	XAV-19 is an intravenous antibody-based treatment targeted towards SARS-CoV-2 and other coronaviruses[L16553,L16558]. The therapy concept is based on COVID-19 convalescent plasma. However, rather than using human plasma, XAV-19 is a...
Etesevimab	Etesevimab in combination with bamlanivimab is used to treat mild to moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients, including neonates, with positive results of direct SARS-CoV-2 viral...
Rurioctocog alfa pegol	A pegylated recombinant human coagulation factor VIII used to treat and prevent bleeding episodes in patients 12 years and above with hemophilia A.
Iseganan	Iseganan is under investigation in clinical trial NCT00022373 (Iseganan Hydrochloride in Preventing Oral Mucositis in Patients Who Are Undergoing Radiation Therapy for Head and Neck Cancer).
Aldafermin	Aldafermin is under investigation in clinical trial NCT03912532 (Evaluation of Efficacy, Safety and Tolerability of Aldafermin in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study in Subjects With Nonalcoholic Steatohepatitis...
Bizalimogene ralaplasmid	Bizalimogene ralaplasmid is under investigation in clinical trial NCT03499795 (VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 And/or HPV-18 Related Anal or Anal/peri-anal, High Grade...
Dopastatin	Dopastatin is under investigation in clinical trial NCT04335357 (TBR-760 in Adult Patients With Non-functioning Pituitary Adenomas).
Dynorphin	Dynorphin is under investigation in clinical trial NCT00000244 (Effects of Dynorphin 1-13 on Heroin Addiction - 1).
VEGFR2-169	VEGFR2-169 is under investigation in clinical trial NCT00655785 (Antiangiogenic Peptide Vaccine Therapy With Gemcitabine in Treating Patient With Pancreatic Cancer (Phase1/2)).
Glenzocimab	Not Annotated
Gontivimab	Gontivimab is under investigation in clinical trial NCT03468829 (Efficacy and Safety of ALX-0171 in Adult Hematopoietic Stem Cell Transplant (HSCT) Recipients Who Present With Respiratory Syncytial Virus (RSV) Infection).
Itepekimab	Itepekimab is under investigation in clinical trial NCT03546907 (Proof-of-concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-il-33 Mab) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)).
Kisspeptin-10	Kisspeptin-10 is under investigation in clinical trial NCT03771326 (KP-10 and Insulin Secretion in Men).
Loncastuximab tesirine	An antibody-drug conjugate used for the treatment of relapsed and refractory B-cell lymphomas.
Nirsevimab	Nirsevimab is under investigation in clinical trial NCT03959488 (A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(rsv) Lower Respiratory Track Infection (LRTI)...
Parathyroid Hormone-Related Protein 1-36	Parathyroid Hormone-Related Protein 1-36 is under investigation in clinical trial NCT00853723 (Comparison Study of Pthrp and PTH to Treat Osteoporosis).
Pegylated Recombinant Human Arginase I	Pegylated Recombinant Human Arginase I is under investigation in clinical trial NCT03455140 (A Study Evaluating the Safety and Activity of Pegylated Recombinant Human Arginase (BCT-100)).
Pexiganan	Pexiganan is under investigation in clinical trial NCT01594762 (Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers).
Ribaxamase	Ribaxamase is under investigation in clinical trial NCT02563106 (A Study of SYN-004 for the Prevention of c.diff in Patients With a LRTI).
Glofitamab	Glofitamab is under investigation in clinical trial NCT04408638 (A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants...
Felzartamab	Felzartamab is under investigation in clinical trial NCT04145440 (Trial to Assess Safety and Efficacy of MOR202 in Anti-pla2r + Membranous Nephropathy (Amn)).
Astegolimab	Astegolimab is under investigation in clinical trial NCT04386616 (A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia).
Levilimab	Levilimab is under investigation in clinical trial NCT04227366 (Study of the Efficacy and Safety of BCD-089 in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis).
Axatilimab	Axatilimab is under investigation in clinical trial NCT04301778 (Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-embolization for Patients With Intrahepatic Cholangiocarcinoma).
Zansecimab	Zansecimab is under investigation in clinical trial NCT04342897 (A Study of LY3127804 in Participants With COVID-19).
Avdoralimab	Avdoralimab is under investigation in clinical trial NCT04333914 (Prospective Study in Patients With Advanced or Metastatic Cancer and Sars-cov-2 Infection).
Efineptakin alfa	Efineptakin alfa (also known as NT-I7) is a long-acting human interleukin-7 (IL-7) fusion protein that promotes T-cell development, contributing to the immune response. Compared to endogenous IL-7, NT-I7 is more...
Pidacmeran	Pidacmeran is under investigation in clinical trial NCT04380701 (A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-2019 in Healthy Adults).
BNT-162A1	BNT-162A1 is under investigation in clinical trial NCT04380701 (A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-2019 in Healthy Adults).
Vilobelimab	Vilobelimab is under investigation in clinical trial NCT03895801 (Study of IFX-1 to Replace Steroids in Patients With Granulomatosis With Polyangiitis and Microscopic Polyangiitis).
Narsoplimab	An anti-MASP-2 antibody currently being investigated for use in transplant-associated thrombotic microangiopathies and IgA nephropathy.
EpiVacCorona	EpiVacCorona Vaccine, developed by the Vektor State Research Center of Virology and Biotechnology in Russia, is based on peptide-antigens that facilitate immunity to the SARS-CoV-2 virus . It is currently...
Meplazumab	Meplazumab is a humanized anti-CD147 antibody being investigated as an add-on therapy in patients with COVID-19 pneumonia.
Pam2csk4	Not Available
Inbakicept	Not Available
Collagen-polyvinylpyrrolidone	Collagen-polyvinylpyrrolidone情况共聚物ated from a mixture of type I collagen and low-molecular-weight PVP that has undergone γ irradiation . It is characterized by antifibrotic, fibrolytic, and immunomodulatory properties...
Dialyzable leukocyte extract	Transferon is comprised of several peptides mixed from human dialyzable leucocyte extracts and acts as an immunomodulator. It is thought to have widespread effects on the immune system, and effective...
Lactoferrin	Lactoferrin is under investigation in clinical trial NCT03748043 (The Effectiveness of Lactoferrin in Treatment of Iron Deficiency Anemia in Children With Chronic Tonsillitis).
Succinylated gelatin	A plasma volume expander indicated alone or in combination with blood transfusions.
Amlintide	A medication used in combination with corticosteroids for the treatment of hemorrhoids.
Efanesoctocog alfa	Efanesoctocog alfa is under investigation in clinical trial NCT04759131 (Safety, Efficacy and PK of BIVV001 in Pediatric Patients With Hemophilia A).
Idecabtagene vicleucel	An autologous T-cell therapy indicated to treat relapsed or refractory multiple myeloma.
Ianalumab	Ianalumab is under investigation in clinical trial NCT01930175 (Study of Efficacy and Safety of VAY736 in Patients With Pemphigus Vulgaris).
Budigalimab	Budigalimab is under investigation in clinical trial NCT04807972 (Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 Is Administered in Combination With IV...
Abelacimab	Abelacimab is under investigation in clinical trial NCT04755283 (Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation).
Reltecimod	Reltecimod is under investigation in clinical trial NCT02469857 (Phase III Efficacy and Safety Study of AB103 in the Treatment of Patients With Necrotizing Soft Tissue Infections).
Tengonermin	Tengonermin, also known as NGR-hTNF, is a vascular-targeting drug. It is a recombinant protein and peptide-targeted agent consisting of the human Tumour Necrosis Factor-α (TNF-α) conjugated with the CNGRCG peptide....
Corynebacterium diphtheriae CRM197 protein	Not Annotated
Lirentelimab	Lirentelimab is under investigation in clinical trial NCT04856891 (A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Duodenitis).
Enibarcimab	Enibarcimab is under investigation in clinical trial NCT03989531 (Adrecizumab in Cardiogenic Shock).
Tisotumab vedotin	A tissue factor-directed antibody drug conjugate that is used to treat adults with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.
Bebtelovimab	A human IgG1κ monoclonal antibody targeted against the spike protein of SARS-CoV-2 which is used in the treatment of mild-to-moderate COVID-19.
Priliximab	Not Annotated
Myelin basic protein	Not Annotated
Interferon tau	Not Annotated
TOL-101	Not Annotated
Botulinum toxin type F	Not Annotated
Tilavonemab	Not Annotated

Drugs & Drug Targets

Drug	Target	Type
Lepirudin	Prothrombin	target
Cetuximab	Epidermal growth factor receptor	target
Cetuximab	Low affinity immunoglobulin gamma Fc region receptor III-B	target
Cetuximab	Complement C1q subcomponent subunit A	target
Cetuximab	Complement C1q subcomponent subunit B	target
Cetuximab	Complement C1q subcomponent subunit C	target
Cetuximab	Low affinity immunoglobulin gamma Fc region receptor III-A	target
Cetuximab	High affinity immunoglobulin gamma Fc receptor I	target
Cetuximab	Low affinity immunoglobulin gamma Fc region receptor II-a	target
Dornase alfa	DNA	target
Denileukin diftitox	Interleukin-2 receptor subunit alpha	target
Denileukin diftitox	Cytokine receptor common subunit gamma	target
Denileukin diftitox	Interleukin-2 receptor subunit beta	target
Etanercept	Tumor necrosis factor	target
Etanercept	Lymphotoxin-alpha	target
Etanercept	Low affinity immunoglobulin gamma Fc region receptor III-B	target
Etanercept	Low affinity immunoglobulin gamma Fc region receptor III-A	target
Etanercept	High affinity immunoglobulin gamma Fc receptor I	target
Etanercept	Low affinity immunoglobulin gamma Fc region receptor II-a	target
Etanercept	Low affinity immunoglobulin gamma Fc region receptor II-b	target
Etanercept	Low affinity immunoglobulin gamma Fc region receptor II-c	target
Etanercept	Complement component 1q (C1q)	target
Leuprolide	Gonadotropin-releasing hormone receptor	target
Peginterferon alfa-2a	Interferon alpha/beta receptor 2	target
Peginterferon alfa-2a	Interferon alpha/beta receptor 1	target
Peginterferon alfa-2a	Cytochrome P450 1A2	enzyme
Alteplase	Fibrinogen alpha chain	target
Alteplase	Plasminogen	target
Alteplase	Plasminogen activator inhibitor 1	target
Alteplase	Fibrinogen gamma chain	target
Interferon alfa-n1	Interferon alpha/beta receptor 2	target
Interferon alfa-n1	Interferon alpha/beta receptor 1	target
Interferon alfa-n1	Cytochrome P450 1A2	enzyme
Darbepoetin alfa	Erythropoietin receptor	target
Urokinase	Urokinase plasminogen activator surface receptor	target
Urokinase	Plasminogen	target
Urokinase	Plasminogen activator inhibitor 2	target
Urokinase	Plasminogen activator inhibitor 1	target
Urokinase	Plasma serine protease inhibitor	target
Urokinase	Nidogen-1	target
Urokinase	Low-density lipoprotein receptor-related protein 2	target
Urokinase	Suppressor of tumorigenicity 14 protein	target
Urokinase	巨噬细胞metalloelastase	enzyme
Reteplase	Fibrinogen alpha chain	target
Reteplase	Plasminogen	target
Reteplase	Plasminogen activator inhibitor 1	target
Erythropoietin	Erythropoietin receptor	target
Salmon calcitonin	Calcitonin receptor	target
Interferon alfa-n3	Interferon alpha/beta receptor 1	target
Interferon alfa-n3	Interferon alpha/beta receptor 2	target
Interferon alfa-n3	Cytochrome P450 1A2	enzyme
Pegfilgrastim	Granulocyte colony-stimulating factor receptor	target
Pegfilgrastim	Neutrophil elastase	enzyme
Sargramostim	Granulocyte-macrophage colony-stimulating factor receptor subunit alpha	target
Sargramostim	Bone marrow proteoglycan	target
Sargramostim	Interleukin-3 receptor subunit alpha	target
Sargramostim	Cytokine receptor common subunit beta	target
Sargramostim	Syndecan-2	target
Peginterferon alfa-2b	Interferon alpha/beta receptor 1	target
Peginterferon alfa-2b	Interferon alpha/beta receptor 2	target
Peginterferon alfa-2b	Cytochrome P450 1A2	enzyme
Peginterferon alfa-2b	Cytochrome P450 2D6	enzyme
Peginterferon alfa-2b	Cytochrome P450 2C9	enzyme
Antihemophilic factor, human recombinant	Coagulation factor X	target
Antihemophilic factor, human recombinant	Phytanoyl-CoA dioxygenase, peroxisomal	target
Antihemophilic factor, human recombinant	Coagulation factor IX	target
Antihemophilic factor, human recombinant	Asialoglycoprotein receptor 2	target
Antihemophilic factor, human recombinant	78 kDa glucose-regulated protein	target
Antihemophilic factor, human recombinant	Calreticulin	target
Antihemophilic factor, human recombinant	Calnexin	target
Antihemophilic factor, human recombinant	Protein ERGIC-53	target
Antihemophilic factor, human recombinant	Prolow-density lipoprotein receptor-related protein 1	target
Antihemophilic factor, human recombinant	Multiple coagulation factor deficiency protein 2	target
Antihemophilic factor, human recombinant	von Willebrand factor	target
Antihemophilic factor, human recombinant	Prothrombin	enzyme
Antihemophilic factor, human recombinant	Vitamin K-dependent protein C	enzyme
Anakinra	Interleukin-1 receptor type 1	target
Gramicidin D	P-glycoprotein 1	transporter
Human immunoglobulin G	Low affinity immunoglobulin gamma Fc region receptor III-B	target
Human immunoglobulin G	Low affinity immunoglobulin gamma Fc region receptor III-A	target
Human immunoglobulin G	High affinity immunoglobulin gamma Fc receptor I	target
Human immunoglobulin G	Low affinity immunoglobulin gamma Fc region receptor II-a	target
Human immunoglobulin G	Low affinity immunoglobulin gamma Fc region receptor II-b	target
Human immunoglobulin G	Low affinity immunoglobulin gamma Fc region receptor II-c	target
Human immunoglobulin G	High affinity immunoglobulin gamma Fc receptor IB	target
Human immunoglobulin G	Complement C3	target
Human immunoglobulin G	Complement C4-A	target
Human immunoglobulin G	Complement C4-B	target
Human immunoglobulin G	Complement C5	target
Interferon gamma-1b	Interferon gamma receptor 1	target
Interferon gamma-1b	Interferon gamma receptor 2	target
Interferon gamma-1b	Cytochrome P450 1A2	enzyme
Desmopressin	Vasopressin V1a receptor	target
Desmopressin	Vasopressin V1b receptor	target
Desmopressin	Vasopressin V2 receptor	target
Desmopressin	Prostaglandin G/H synthase 1	enzyme
Desmopressin	Prostaglandin G/H synthase 2	enzyme
Coagulation factor VIIa Recombinant Human	Coagulation factor X	target
Coagulation factor VIIa Recombinant Human	Tissue factor	target
Coagulation factor VIIa Recombinant Human	Tissue factor pathway inhibitor	target
Coagulation factor VIIa Recombinant Human	Vitamin K-dependent gamma-carboxylase	target
Coagulation factor VIIa Recombinant Human	Coagulation factor VII	target
Palifermin	Fibroblast growth factor receptor 2	target
Palifermin	Fibroblast growth factor receptor 1	target
Palifermin	Basement membrane-specific heparan sulfate proteoglycan core protein	target
Glucagon	Glucagon receptor	target
Glucagon	Glucagon-like peptide 2 receptor	target
Glucagon	Glucagon-like peptide 1 receptor	target
Aldesleukin	Interleukin-2 receptor subunit beta	target
Aldesleukin	Interleukin-2 receptor subunit alpha	target
Aldesleukin	Cytokine receptor common subunit gamma	target
Aldesleukin	Prostaglandin G/H synthase 2	enzyme
Aldesleukin	Cytosolic phospholipase A2	enzyme
Aldesleukin	Cytochrome P450 3A4	enzyme
Aldesleukin	Xanthine dehydrogenase/oxidase	enzyme
Aldesleukin	Cytochrome P450 2E1	enzyme
Botulinum toxin type B	Vesicle-associated membrane protein 1	target
Botulinum toxin type B	Vesicle-associated membrane protein 2	target
Botulinum toxin type B	Synaptotagmin-2	target
Omalizumab	High affinity immunoglobulin epsilon receptor subunit alpha	target
Omalizumab	High affinity immunoglobulin epsilon receptor subunit beta	target
Adalimumab	Tumor necrosis factor	target
Abciximab	Integrin beta-3	target
Abciximab	Low affinity immunoglobulin gamma Fc region receptor II-a	target
Abciximab	Low affinity immunoglobulin gamma Fc region receptor II-b	target
Abciximab	Integrin alpha-IIb	target
Abciximab	Vitronectin	target
Gemtuzumab ozogamicin	Myeloid cell surface antigen CD33	target
Gemtuzumab ozogamicin	Low affinity immunoglobulin gamma Fc region receptor III-B	target
Gemtuzumab ozogamicin	Low affinity immunoglobulin gamma Fc region receptor III-A	target
Gemtuzumab ozogamicin	High affinity immunoglobulin gamma Fc receptor I	target
Indium In-111 satumomab pendetide	Tumor-associated glycoprotein 72 (TAG-72)	target
Alpha-1-proteinase inhibitor	Neutrophil elastase	target
Albumin human	Nitric oxide	target
Infliximab	Tumor necrosis factor	target
Follitropin	Follicle-stimulating hormone receptor	target
Vasopressin	Vasopressin V1a receptor	target
Vasopressin	Vasopressin V2 receptor	target
Vasopressin	Vasopressin V1b receptor	target
Vasopressin	Canalicular multispecific organic anion transporter 1	transporter
Vasopressin	催产素受体	target
Interferon beta-1b	Interferon alpha/beta receptor 1	target
Interferon beta-1b	Interferon alpha/beta receptor 2	target
Interferon beta-1b	Cytochrome P450 1A2	enzyme
Insulin pork	Insulin receptor	target
Insulin pork	Insulin-like growth factor 1 receptor	target
Insulin pork	Cytochrome P450 1A2	enzyme
Insulin pork	Insulin-degrading enzyme	enzyme
Trastuzumab	Receptor tyrosine-protein kinase erbB-2	target
Rituximab	B-lymphocyte antigen CD20	target
Basiliximab	Interleukin-2 receptor subunit alpha	target
Basiliximab	Interleukin-2 receptor subunit beta	target
Muromonab	T-cell surface glycoprotein CD3 epsilon chain	target
Muromonab	Low affinity immunoglobulin gamma Fc region receptor III-B	target
Muromonab	T-cell surface glycoprotein CD3 delta chain	target
Muromonab	T-cell surface glycoprotein CD3 gamma chain	target
Muromonab	T-cell surface glycoprotein CD3 zeta chain	target
Ibritumomab tiuxetan	B-lymphocyte antigen CD20	target
Tositumomab	B-lymphocyte antigen CD20	target
Tositumomab	Low affinity immunoglobulin gamma Fc region receptor II-b	target
Botulinum toxin type A	Synaptosomal-associated protein 25	target
Botulinum toxin type A	Rho-related GTP-binding protein RhoB	target
Botulinum toxin type A	Serum albumin	carrier
Alemtuzumab	CAMPATH-1 antigen	target
Alemtuzumab	Low affinity immunoglobulin gamma Fc region receptor III-B	target
Alemtuzumab	Low affinity immunoglobulin gamma Fc region receptor III-A	target
Alemtuzumab	High affinity immunoglobulin gamma Fc receptor I	target
Alemtuzumab	Low affinity immunoglobulin gamma Fc region receptor II-a	target
Alemtuzumab	Low affinity immunoglobulin gamma Fc region receptor II-b	target
Alemtuzumab	Low affinity immunoglobulin gamma Fc region receptor II-c	target
Capromab pendetide	Glutamate carboxypeptidase 2	target
Efalizumab	Integrin alpha-L	target
Efalizumab	Integrin alpha-X	target
Antithymocyte immunoglobulin (rabbit)	T-cell surface glycoprotein CD1a	target
Antithymocyte immunoglobulin (rabbit)	Major histocompatibility complex class I-related gene protein	target
Antithymocyte immunoglobulin (rabbit)	Integrin alpha-L	target
Antithymocyte immunoglobulin (rabbit)	T-lymphocyte activation antigen CD86	target
Antithymocyte immunoglobulin (rabbit)	Low affinity immunoglobulin gamma Fc region receptor II-b	target
Antithymocyte immunoglobulin (rabbit)	T-cell surface glycoprotein CD4	target
Antithymocyte immunoglobulin (rabbit)	Integrin beta-1	target
Antithymocyte immunoglobulin (rabbit)	Integrin alpha-V	target
Antithymocyte immunoglobulin (rabbit)	Integrin beta-3	target
Filgrastim	Granulocyte colony-stimulating factor receptor	target
Filgrastim	Neutrophil elastase	enzyme
Becaplermin	Platelet-derived growth factor receptor beta	target
Becaplermin	Alpha-2-macroglobulin	target
Becaplermin	Platelet-derived growth factor receptor alpha	target
Agalsidase beta	Globotriaosylceramide	target
Agalsidase beta	Cation-dependent mannose-6-phosphate receptor	transporter
Natalizumab	Integrin alpha-4	target
Natalizumab	Low affinity immunoglobulin gamma Fc region receptor III-B	target
Natalizumab	High affinity immunoglobulin gamma Fc receptor I	target
Natalizumab	Intercellular adhesion molecule 1	target
Enfuvirtide	Envelope glycoprotein	target
Enfuvirtide	Cytochrome P450 2C19	enzyme
Enfuvirtide	Cytochrome P450 2E1	enzyme
Palivizumab	Fusion glycoprotein F0	target
Palivizumab	Low affinity immunoglobulin gamma Fc region receptor III-B	target
Palivizumab	Complement C1r subcomponent	target
Palivizumab	Complement C1q subcomponent subunit A	target
Palivizumab	Complement C1q subcomponent subunit B	target
Palivizumab	Complement C1q subcomponent subunit C	target
Palivizumab	Low affinity immunoglobulin gamma Fc region receptor III-A	target
Palivizumab	High affinity immunoglobulin gamma Fc receptor I	target
Palivizumab	Low affinity immunoglobulin gamma Fc region receptor II-b	target
Daclizumab	Interleukin-2 receptor subunit alpha	target
Daclizumab	Low affinity immunoglobulin gamma Fc region receptor III-B	target
Daclizumab	Complement C1r subcomponent	target
Daclizumab	Complement C1q subcomponent subunit A	target
Daclizumab	Complement C1q subcomponent subunit B	target
Daclizumab	Complement C1q subcomponent subunit C	target
Daclizumab	Low affinity immunoglobulin gamma Fc region receptor III-A	target
Daclizumab	High affinity immunoglobulin gamma Fc receptor I	target
Daclizumab	Low affinity immunoglobulin gamma Fc region receptor II-a	target
Daclizumab	Interleukin-2 receptor subunit beta	target
Daclizumab	Low affinity immunoglobulin gamma Fc region receptor II-b	target
Daclizumab	Low affinity immunoglobulin gamma Fc region receptor II-c	target
Bevacizumab	Vascular endothelial growth factor A	target
Bevacizumab	Complement C1q subcomponent subunit A	target
Bevacizumab	Complement C1q subcomponent subunit B	target
Bevacizumab	Complement C1q subcomponent subunit C	target
Bevacizumab	Low affinity immunoglobulin gamma Fc region receptor III-A	target
Bevacizumab	Low affinity immunoglobulin gamma Fc region receptor II-a	target
Bevacizumab	Low affinity immunoglobulin gamma Fc region receptor II-b	target
Bevacizumab	Low affinity immunoglobulin gamma Fc region receptor II-c	target
Bevacizumab	High affinity immunoglobulin gamma Fc receptor I	target
Technetium Tc-99m arcitumomab	Carcinoembryonic antigen-related cell adhesion molecule 1	target
Pentagastrin	Gastrin/cholecystokinin type B receptor	target
Pentagastrin	Cholinesterase	enzyme
Eculizumab	Complement C5	target
Panitumumab	Epidermal growth factor receptor	target
Ranibizumab	Vascular endothelial growth factor A	target
Mecasermin	Insulin-like growth factor 1 receptor	target
Mecasermin	Insulin-like growth factor-binding protein 3	target
Mecasermin	Insulin receptor	target
Mecasermin	Cation-independent mannose-6-phosphate receptor	target
Mecasermin	Insulin-like growth factor-binding protein 3	carrier
Mecasermin	Insulin-like growth factor-binding protein complex acid labile subunit	carrier
Mecasermin	Insulin-like growth factor-binding protein 1	carrier
Mecasermin	Insulin-like growth factor-binding protein 2	carrier
Mecasermin	Insulin-like growth factor-binding protein 4	carrier
Mecasermin	Insulin-like growth factor-binding protein 5	carrier
Mecasermin	Insulin-like growth factor-binding protein 6	carrier
Insulin glulisine	Insulin receptor	target
Insulin glulisine	Insulin-like growth factor 1 receptor	target
Insulin glulisine	Cytochrome P450 1A2	enzyme
Galiximab	T-lymphocyte activation antigen CD80	target
Afamelanotide	Melanocyte-stimulating hormone receptor	target
Afelimomab	Tumor necrosis factor	target
Epratuzumab	B-cell receptor CD22	target
Oregovomab	Mucin-16	target
IGN311	Epidermal growth factor receptor	target
IGN311	Receptor tyrosine-protein kinase erbB-2	target
Labetuzumab	Carcinoembryonic antigen-related cell adhesion molecule 5	target
Matuzumab	Epidermal growth factor receptor	target
Fontolizumab	Interferon gamma	target
CR002	Platelet-derived growth factor D	target
Rozrolimupab	Rhesus blood group D antigen	target
Hepatitis B immune globulin	HBsAg	target
Oportuzumab monatox	Epithelial cell adhesion molecule	target
Briakinumab	Interleukin-12 subunit beta	target
Briakinumab	Interleukin-23 subunit alpha	target
Iratumumab	Tumor necrosis factor receptor superfamily member 8	target
Ramucirumab	Vascular endothelial growth factor receptor 2	target
Farletuzumab	Folate receptor alpha	target
Ustekinumab	Interleukin-12 subunit beta	target
Ustekinumab	Interleukin-23	target
Trastuzumab emtansine	Receptor tyrosine-protein kinase erbB-2	target
Trastuzumab emtansine	P-glycoprotein 1	transporter
Trastuzumab emtansine	Cytochrome P450 3A4	enzyme
Trastuzumab emtansine	Cytochrome P450 3A5	enzyme
PRO-542	Free fatty acid receptor 4	target
TNX-901	High affinity immunoglobulin epsilon receptor subunit alpha	target
Inotuzumab ozogamicin	P-glycoprotein 1	transporter
Inotuzumab ozogamicin	B-cell receptor CD22	target
RI 624	Beta-nerve growth factor	target
Stamulumab	Growth/differentiation factor 8	target
Leronlimab	C-C chemokine receptor type 5	target
Glembatumumab vedotin	Transmembrane glycoprotein NMB	target
Olaratumab	Platelet-derived growth factor receptor alpha	target
TB-402	Coagulation factor VIII	target
Caplacizumab	von Willebrand factor	target
IMC-1C11	Vascular endothelial growth factor receptor 1	target
IMC-1C11	Vascular endothelial growth factor receptor 2	target
IMC-1C11	Vascular endothelial growth factor receptor 3	target
Eldelumab	C-X-C motif chemokine 10	target
Lumiliximab	Low affinity immunoglobulin epsilon Fc receptor	target
Canakinumab	Interleukin-1 beta	target
Ipilimumab	Cytotoxic T-lymphocyte protein 4	target
Clenoliximab	T-cell surface glycoprotein CD4	target
Tocilizumab	Interleukin-6 receptor subunit alpha	target
Tocilizumab	Cytochrome P450 3A4	enzyme
Elotuzumab	SLAM family member 7	target
AVE9633	Myeloid cell surface antigen CD33	target
AVE9633	Cytochrome P450 3A4	enzyme
Carotuximab	Endoglin	target
XmAb 2513	Tumor necrosis factor receptor superfamily member 8	target
Coltuximab ravtansine	淋巴球抗原CD19	target
Coltuximab ravtansine	Cytochrome P450 3A4	enzyme
Teprotumumab	Insulin-like growth factor 1 receptor	target
Lucatumumab	Tumor necrosis factor receptor superfamily member 5	target
Pertuzumab	Receptor tyrosine-protein kinase erbB-2	target
Siplizumab	T-cell surface antigen CD2	target
Human C1-esterase inhibitor	Complement C1r subcomponent	target
Human C1-esterase inhibitor	Complement C1s subcomponent	target
Human C1-esterase inhibitor	Plasma kallikrein	target
Human C1-esterase inhibitor	Coagulation factor XII	target
Human C1-esterase inhibitor	Prothrombin	target
Human C1-esterase inhibitor	Coagulation factor XI	target
Human C1-esterase inhibitor	Tissue-type plasminogen activator	target
Sibrotuzumab	Seprase	target
Bivatuzumab	CD44 antigen	target
Lexatumumab	Tumor necrosis factor receptor superfamily member 10B	target
Reslizumab	Interleukin-5	target
Teplizumab	T-cell surface glycoprotein CD3 epsilon chain	target
Catumaxomab	Epithelial cell adhesion molecule	target
Catumaxomab	Low affinity immunoglobulin gamma Fc region receptor II-a	target
Catumaxomab	Low affinity immunoglobulin gamma Fc region receptor III-A	target
Catumaxomab	Low affinity immunoglobulin gamma Fc region receptor III-B	target
Catumaxomab	T-cell surface glycoprotein CD3 epsilon chain	target
Catumaxomab	High affinity immunoglobulin gamma Fc receptor I	target
Mepolizumab	Interleukin-5	target
Denosumab	肿瘤坏死因子配体超家族成员11	target
Ofatumumab	B-lymphocyte antigen CD20	target
Liraglutide	Glucagon-like peptide 1 receptor	target
Liraglutide	Dipeptidyl peptidase 4	enzyme
Liraglutide	Neprilysin	enzyme
Liraglutide	Serum albumin	carrier
Golimumab	Tumor necrosis factor	target
Aprotinin	Trypsin-1	target
Aprotinin	Chymotrypsinogen B	target
Aprotinin	Plasminogen	target
Aprotinin	Kallikrein-1	target
Aprotinin	Cholinesterase	enzyme
Brentuximab vedotin	Tumor necrosis factor receptor superfamily member 8	target
Brentuximab vedotin	Cytochrome P450 3A4	enzyme
Brentuximab vedotin	ATP-binding cassette sub-family B member 5	transporter
Belimumab	Tumor necrosis factor ligand superfamily member 13B	target
Raxibacumab	Protective antigen	target
Certolizumab pegol	Tumor necrosis factor	target
Certolizumab pegol	Alcohol dehydrogenase [NADP(+)]	enzyme
Obinutuzumab	B-lymphocyte antigen CD20	target
Secukinumab	Interleukin-17A	target
Vedolizumab	Integrin alpha-4	target
Vedolizumab	Integrin beta-7	target
Nivolumab	Programmed cell death protein 1	target
Nivolumab	Programmed cell death 1 ligand 1	target
Siltuximab	Interleukin-6	target
Siltuximab	Cytochrome P450 3A4	enzyme
Pembrolizumab	Programmed cell death protein 1	target
Pembrolizumab	Programmed cell death 1 ligand 1	target
Dulaglutide	Glucagon-like peptide 1 receptor	target
Metreleptin	Leptin receptor	target
Blinatumomab	淋巴球抗原CD19	target
Blinatumomab	T-cell surface glycoprotein CD3 delta chain	target
Dinutuximab	GD2 disialoganglioside	target
Asfotase alfa	Pyrophosphate	target
Peginterferon beta-1a	Cytochrome P450 1A2	enzyme
Peginterferon beta-1a	Interferon alpha/beta receptor 1	target
Protamine sulfate	Coagulation factor X	target
Protamine sulfate	Antithrombin-III	target
Alirocumab	Proprotein convertase subtilisin/kexin type 9	target
Evolocumab	Proprotein convertase subtilisin/kexin type 9	target
Daratumumab	ADP-ribosyl cyclase 1	target
Necitumumab	Epidermal growth factor receptor	target
Protein C	Coagulation factor V	target
Protein C	Coagulation factor VIII	target
Ixekizumab	Interleukin-17A	target
Atezolizumab	Programmed cell death 1 ligand 1	target
Atezolizumab	Programmed cell death protein 1	target
Antithrombin III human	Antithrombin-III	target
Bremelanotide	Melanocyte-stimulating hormone receptor	target
Bremelanotide	Melanocortin receptor 4	target
Bremelanotide	Melanocortin receptor 3	target
Bremelanotide	Melanocortin receptor 5	target
Bremelanotide	Adrenocorticotropic hormone receptor	target
Setmelanotide	Melanocortin receptor 4	target
Durvalumab	Programmed cell death 1 ligand 1	target
Durvalumab	Programmed cell death protein 1	target
Sarilumab	Cytochrome P450 3A4	enzyme
Sarilumab	Interleukin-6 receptor subunit alpha	target
Sarilumab	High affinity immunoglobulin gamma Fc receptor I	target
Sarilumab	Low affinity immunoglobulin gamma Fc region receptor II-a	target
Sarilumab	Low affinity immunoglobulin gamma Fc region receptor II-b	target
Sarilumab	Low affinity immunoglobulin gamma Fc region receptor III-A	target
Sarilumab	Low affinity immunoglobulin gamma Fc region receptor III-B	target
Tremelimumab	Cytotoxic T-lymphocyte protein 4	target
Guselkumab	Interleukin-23 subunit alpha	target
Dalotuzumab	Insulin-like growth factor 1 receptor	target
Ligelizumab	Immunoglobulin heavy constant epsilon	target
Romosozumab	Sclerostin	target
Avelumab	Programmed cell death 1 ligand 1	target
Avelumab	Programmed cell death protein 1	target
Anifrolumab	Interferon alpha/beta receptor 1	target
Ocrelizumab	B-lymphocyte antigen CD20	target
Gantenerumab	Amyloid beta A4 protein	target
Lorvotuzumab mertansine	Cytochrome P450 3A4	enzyme
Sotatercept	Activin receptor type-2A	target
Gevokizumab	Interleukin-1 beta	target
Dupilumab	Interleukin-4 receptor subunit alpha	target
Dupilumab	Interleukin-13	target
Dupilumab	Interleukin-4	target
Tralokinumab	Interleukin-13	target
Etrolizumab	Integrin beta-7	target
Polatuzumab vedotin	Cytochrome P450 3A4	enzyme
Polatuzumab vedotin	B-cell antigen receptor complex-associated protein beta chain	transporter
Polatuzumab vedotin	B-cell antigen receptor complex-associated protein beta chain	target
Cixutumumab	Insulin-like growth factor 1 receptor	target
Aducanumab	Amyloid beta A4 protein	target
Mirvetuximab Soravtansine	Cytochrome P450 3A4	enzyme
Mogamulizumab	C-C chemokine receptor type 4	target
Inebilizumab	淋巴球抗原CD19	target
Dacetuzumab	Tumor necrosis factor receptor superfamily member 5	target
Ibalizumab	T-cell surface glycoprotein CD4	target
Ibalizumab	C-C chemokine receptor type 5	target
Ibalizumab	C-X-C chemokine receptor type 4	target
Amatuximab	Mesothelin	target
Sacituzumab govitecan	Tumor-associated calcium signal transducer 2	target
Sacituzumab govitecan	DNA topoisomerase 1	target
Sacituzumab govitecan	Far upstream element-binding protein 1	target
Sacituzumab govitecan	UDP-glucuronosyltransferase 1-1	enzyme
Olokizumab	Interleukin-6	target
Emicizumab	Coagulation factor IX	target
Emicizumab	Coagulation factor X	target
Semaglutide	Serum albumin	carrier
Semaglutide	Dipeptidyl peptidase 4	enzyme
Semaglutide	Neprilysin	enzyme
Semaglutide	Glucagon-like peptide 1 receptor	target
Semaglutide	Lipoprotein lipase	enzyme
Semaglutide	Alpha-amylase 1	enzyme
Besilesomab	Carcinoembryonic antigen	target
Tildrakizumab	Interleukin-23	target
Tildrakizumab	Cytochrome P450 4A11	enzyme
Erenumab	Calcitonin gene-related peptide type 1 receptor	target
Fremanezumab	Calcitonin gene-related peptide 1	target
Fremanezumab	Calcitonin gene-related peptide 2	target
Lanadelumab	Plasma kallikrein	target
Moxetumomab pasudotox	B-cell receptor CD22	target
Moxetumomab pasudotox	Elongation factor 2	target
Elapegademase	Adenosine	target
Lebrikizumab	Interleukin-13	target
Lebrikizumab	IL13 protein	target
Benralizumab	Interleukin-5 receptor subunit alpha	target
Benralizumab	Low affinity immunoglobulin gamma Fc region receptor III-A	target
Zalutumumab	Epidermal growth factor receptor	target
Plozalizumab	C-C chemokine receptor type 2	target
Sifalimumab	Interferon alpha-2	target
Emapalumab	Interferon gamma	target
Turoctocog alfa pegol	Vitamin K-dependent protein C	enzyme
Turoctocog alfa pegol	Coagulation factor X	enzyme
Turoctocog alfa pegol	Coagulation factor IX	target
Turoctocog alfa pegol	Coagulation factor X	target
Turoctocog alfa pegol	Prothrombin	target
Turoctocog alfa pegol	von Willebrand factor	target
Polymyxin B	Bacterial outer membrane	target
Polymyxin B	Solute carrier family 15 member 2	transporter
Girentuximab	Carbonic anhydrase 9	target
Girentuximab	Interleukin-2	target
Risankizumab	Interleukin-23	target
Isatuximab	ADP-ribosyl cyclase 1	target
Human interferon beta	Cytochrome P450 1A2	enzyme
Human interferon beta	Interferon alpha/beta receptor 1	target
Human interferon beta	Serum albumin	carrier
CT-011	Programmed cell death protein 1	target
Thrombin alfa	Coagulation factor VIII	target
Thrombin alfa	Coagulation factor V	target
Thrombin alfa	Fibrinogen alpha chain	target
Thrombin alfa	Fibrinogen beta chain	target
Thrombin alfa	Fibrinogen gamma chain	target
Ravulizumab	Complement C5	target
Depatuxizumab mafodotin	Epidermal growth factor receptor	target
Depatuxizumab mafodotin	Tubulin beta chain	target
Depatuxizumab mafodotin	淋巴球抗原CD19	target
Ublituximab	B-lymphocyte antigen CD20	target
Urelumab	Tumor necrosis factor receptor superfamily member 9	target
Fasinumab	Beta-nerve growth factor	target
Vanucizumab	Angiopoietin-2	target
Vanucizumab	Vascular endothelial growth factor A	target
Bimekizumab	Interleukin-17A	target
Bimekizumab	Interleukin-17F	target
Bezlotoxumab	Clostridium difficile Toxin B	target
Tisagenlecleucel	淋巴球抗原CD19	target
Burosumab	Fibroblast growth factor 23	target
Eptinezumab	Calcitonin gene-related peptide 1	target
Eptinezumab	Calcitonin gene-related peptide 2	target
Galcanezumab	Calcitonin gene-related peptide 1	target
Galcanezumab	Calcitonin gene-related peptide 2	target
Cemiplimab	Programmed cell death protein 1	target
Tagraxofusp	Interleukin-3 receptor subunit alpha	target
Tagraxofusp	ADP-ribosylation factor-like protein 2	target
Camrelizumab	Programmed cell death protein 1	target
Camrelizumab	Programmed cell death 1 ligand 1	target
Brolucizumab	Vascular endothelial growth factor A	target
Trastuzumab deruxtecan	P-glycoprotein 1	transporter
Trastuzumab deruxtecan	High affinity immunoglobulin gamma Fc receptor I	target
Trastuzumab deruxtecan	DNA topoisomerase 1	target
Trastuzumab deruxtecan	Lysosomal alpha-glucosidase	enzyme
Trastuzumab deruxtecan	DNA topoisomerase 1	enzyme
Trastuzumab deruxtecan	Cathepsin B	enzyme
Trastuzumab deruxtecan	Cathepsin L1	enzyme
Trastuzumab deruxtecan	Cytochrome P450 3A4	enzyme
Trastuzumab deruxtecan	Solute carrier organic anion transporter family member 1B1	transporter
Trastuzumab deruxtecan	Solute carrier organic anion transporter family member 1B3	transporter
Trastuzumab deruxtecan	Multidrug and toxin extrusion protein 2	transporter
Trastuzumab deruxtecan	Multidrug resistance-associated protein 1	transporter
Trastuzumab deruxtecan	ATP-binding cassette sub-family G member 2	transporter
Margetuximab	Receptor tyrosine-protein kinase erbB-2	target
Tafasitamab	淋巴球抗原CD19	target
Tezepelumab	Thymic stromal lymphopoietin	target
Evinacumab	Angiopoietin-related protein 3	target
Inolimomab	Interleukin-2 receptor subunit alpha	target
Belantamab mafodotin	Solute carrier organic anion transporter family member 1B1	transporter
Belantamab mafodotin	Solute carrier organic anion transporter family member 1B3	transporter
Belantamab mafodotin	Multidrug resistance-associated protein 1	transporter
Belantamab mafodotin	Canalicular multispecific organic anion transporter 1	transporter
Belantamab mafodotin	Canalicular multispecific organic anion transporter 2	transporter
Belantamab mafodotin	Bile salt export pump	transporter
Belantamab mafodotin	P-glycoprotein 1	transporter
Belantamab mafodotin	Tumor necrosis factor receptor superfamily member 17	target
Agalsidase alfa	Cation-dependent mannose-6-phosphate receptor	transporter
Agalsidase alfa	Globotriaosylceramide	target
Olinvacimab	Vascular endothelial growth factor receptor 2	target
Otlertuzumab	Leukocyte antigen CD37	target
Tetanus immune globulin, human	Tetanus toxin	target
Digoxin Immune Fab (Ovine)	Digoxin	target
Anthrax immune globulin human	Protective antigen	target
Crizanlizumab	P-selectin	target
Enfortumab vedotin	Cytochrome P450 3A4	enzyme
Enfortumab vedotin	Nectin-4	target
Enfortumab vedotin	P-glycoprotein 1	transporter
Satralizumab	Interleukin-6 receptor subunit alpha	target
Odesivimab	Envelope glycoprotein	target
Maftivimab	Envelope glycoprotein	target
Atoltivimab	Envelope glycoprotein	target
Bamlanivimab	Spike glycoprotein	target
Naxitamab	GD2 disialoganglioside	target
Ansuvimab	Envelope glycoprotein	target
Human Rho(D) immune globulin	Rhesus blood group D antigen	target
Cusatuzumab	CD70 antigen	target
Dostarlimab	Programmed cell death protein 1	target
Faricimab	Vascular endothelial growth factor A	target
Faricimab	Angiopoietin-2	target
Mosunetuzumab	B-lymphocyte antigen CD20	target
Mosunetuzumab	T-cell surface glycoprotein CD3 epsilon chain	target
Pascolizumab	Interleukin-4	target
Ruplizumab	CD40 ligand	target
Spartalizumab	Programmed cell death protein 1	target
Tislelizumab	Programmed cell death protein 1	target
Amivantamab	Epidermal growth factor receptor	target
Amivantamab	Hepatocyte growth factor receptor	target
Amivantamab	Low affinity immunoglobulin gamma Fc region receptor III-A	target
Plasminogen	Tissue-type plasminogen activator	enzyme
Plasminogen	Urokinase-type plasminogen activator	enzyme
Sotrovimab	Spike glycoprotein	target
Regdanvimab	Spike glycoprotein	target
Imdevimab	Spike glycoprotein	target
Casirivimab	Spike glycoprotein	target
Cilgavimab	Spike glycoprotein	target
Tixagevimab	Spike glycoprotein	target
Cetrorelix	Lutropin-choriogonadotropic hormone receptor	target
Cetrorelix	Gonadotropin-releasing hormone receptor	target
Citrulline	Nitric oxide synthase, endothelial	target
Citrulline	Argininosuccinate synthase	target
Citrulline	N(G),N(G)-dimethylarginine dimethylaminohydrolase 2	target
Citrulline	Argininosuccinate synthetase, isoform CRA_a	target
Citrulline	N(G),N(G)-dimethylarginine dimethylaminohydrolase 1	target
Citrulline	Ornithine carbamoyltransferase, mitochondrial	target
Citrulline	Nitric oxide synthase, brain	target
Citrulline	Nitric oxide synthase, inducible	target
Citrulline	Protein-arginine deiminase type-4	target
Citrulline	Protein-arginine deiminase type-6	target
Citrulline	Protein-arginine deiminase type-1	target
Citrulline	Protein-arginine deiminase type-3	target
Citrulline	Protein-arginine deiminase type-2	target
Citrulline	Solute carrier family 22 member 6	transporter
Gonadorelin	Gonadotropin-releasing hormone receptor	target
Gonadorelin	Putative gonadotropin-releasing hormone II receptor	target
REV131	Histamine H4 receptor	target
CR665	Kappa-type opioid receptor	target
Albinterferon Alfa-2B	Cytochrome P450 1A2	enzyme
LJP 1082	Beta-2-glycoprotein 1	target
Contulakin-G	Voltage-dependent N-type calcium channel subunit alpha-1B	target
Icatibant	B2 bradykinin receptor	target
Icatibant	Aminopeptidase N	target
Labradimil	B2 bradykinin receptor	target
TG4010	Mucin-1	target
TG4010	Interleukin-2	target
Buserelin	Lutropin-choriogonadotropic hormone receptor	target
Buserelin	Gonadotropin-releasing hormone receptor	target
Buserelin	Cytochrome P450 19A1	enzyme
Ganirelix	Gonadotropin-releasing hormone receptor	target
Histrelin	Gonadotropin-releasing hormone receptor	target
Eflapegrastim	Granulocyte colony-stimulating factor receptor	target
Protein S human	Coagulation factor V	target
Protein S human	Coagulation factor X	target
Protein S human	Vitamin K-dependent protein C	target
Anistreplase	Fibrinogen alpha chain	target
Anistreplase	Plasminogen	target
Anistreplase	Plasminogen activator inhibitor 1	target
Tenecteplase	Urokinase plasminogen activator surface receptor	target
Tenecteplase	Plasminogen activator inhibitor 1	target
Tenecteplase	Fibrinogen alpha chain	target
Tenecteplase	Plasminogen activator inhibitor 2	target
Tenecteplase	Tetranectin	target
Tenecteplase	Keratin, type II cytoskeletal 8	target
Tenecteplase	Annexin A2	target
Tenecteplase	Calreticulin	target
Tenecteplase	Calnexin	target
Tenecteplase	Prolow-density lipoprotein receptor-related protein 1	target
Tenecteplase	Plasminogen	target
Interferon alfa-2a	Interferon alpha/beta receptor 1	target
Interferon alfa-2a	Interferon alpha/beta receptor 2	target
Interferon alfa-2a	Cytochrome P450 1A2	enzyme
Oprelvekin	Interleukin-11 receptor subunit alpha	target
Drotrecogin alfa	Coagulation factor VIII	target
Drotrecogin alfa	Coagulation factor V	target
Drotrecogin alfa	Plasminogen activator inhibitor 1	target
Drotrecogin alfa	Thrombomodulin	target
Drotrecogin alfa	Vitamin K-dependent protein S	target
Drotrecogin alfa	Prothrombin	target
Drotrecogin alfa	Platelet factor 4	target
Drotrecogin alfa	Plasma serine protease inhibitor	target
Drotrecogin alfa	Serpin B6	target
Drotrecogin alfa	Endothelial protein C receptor	target
Interferon beta-1a	Interferon alpha/beta receptor 1	target
Interferon beta-1a	Interferon alpha/beta receptor 2	target
Interferon beta-1a	Cytochrome P450 1A2	enzyme
Interferon alfacon-1	Interferon alpha/beta receptor 1	target
Interferon alfacon-1	Interferon alpha/beta receptor 2	target
Interferon alfacon-1	Cytochrome P450 1A2	enzyme
Streptokinase	Plasminogen	target
Streptokinase	Proteinase-activated receptor 1	target
Streptokinase	Cytosolic phospholipase A2	enzyme
Alefacept	T-cell surface antigen CD2	target
Alefacept	Low affinity immunoglobulin gamma Fc region receptor III-B	target
Alefacept	Low affinity immunoglobulin gamma Fc region receptor III-A	target
Felypressin	Vasopressin V1a receptor	target
Interferon alfa-2b	Interferon alpha/beta receptor 2	target
Interferon alfa-2b	Interferon alpha/beta receptor 1	target
Interferon alfa-2b	Cytochrome P450 1A2	enzyme
Nafarelin	Gonadotropin-releasing hormone receptor	target
Nafarelin	Putative gonadotropin-releasing hormone II receptor	target
Colistin	Bacterial outer membrane	target
Aminolevulinic acid	Delta-aminolevulinic acid dehydratase	target
Aminolevulinic acid	Solute carrier family 15 member 1	transporter
Aminolevulinic acid	Solute carrier family 15 member 2	transporter
Colistimethate	Bacterial outer membrane	target
Paclitaxel	Apoptosis regulator Bcl-2	target
Paclitaxel	Tubulin beta-1 chain	target
Paclitaxel	Cytochrome P450 2C8	enzyme
Paclitaxel	Cytochrome P450 3A4	enzyme
Paclitaxel	Cytochrome P450 3A5	enzyme
Paclitaxel	Cytochrome P450 3A7	enzyme
Paclitaxel	Bile salt export pump	transporter
Paclitaxel	P-glycoprotein 1	transporter
Paclitaxel	Multidrug resistance-associated protein 1	transporter
Paclitaxel	Multidrug resistance-associated protein 7	transporter
Paclitaxel	Cytochrome P450 19A1	enzyme
Paclitaxel	Cytochrome P450 1B1	enzyme
Paclitaxel	Solute carrier organic anion transporter family member 1B3	transporter
Paclitaxel	Nuclear receptor subfamily 1 group I member 2	target
Paclitaxel	Microtubule-associated protein 4	target
Paclitaxel	Microtubule-associated protein 2	target
Paclitaxel	Microtubule-associated protein tau	target
Paclitaxel	Canalicular multispecific organic anion transporter 1	transporter
Pramlintide	Receptor activity-modifying protein 1	target
Pramlintide	Receptor activity-modifying protein 2	target
Pramlintide	Receptor activity-modifying protein 3	target
Pramlintide	Calcitonin receptor	target
Galsulfase	Perilipin-3	target
Galsulfase	Dermatan sulfate	target
Abatacept	T-lymphocyte activation antigen CD80	target
Abatacept	T-lymphocyte activation antigen CD86	target
Abatacept	Cytotoxic T-lymphocyte protein 4	target
Tetracosactide	Adrenocorticotropic hormone receptor	target
Corticotropin	Adrenocorticotropic hormone receptor	target
Corticotropin	Corticoliberin	target
Corticotropin	3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 2	enzyme
Corticotropin	25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial	enzyme
Corticotropin	1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial	enzyme
Corticotropin	Cytochrome P450 3A4	enzyme
Bacteriochlorophyll A	Bacteriochlorophyll a protein	target
Bacteriochlorophyll A	Bacteriochlorophyll a protein	target
Terlipressin	Vasopressin V1a receptor	target
Terlipressin	Vasopressin V2 receptor	target
Terlipressin	Vasopressin V1b receptor	target
Vapreotide	Neurokinin 1 receptor	target
Vapreotide	Somatostatin receptor type 2	target
Vapreotide	Somatostatin receptor type 5	target
Vapreotide	Cytochrome P450 3A4	enzyme
Nesiritide	Atrial natriuretic peptide receptor 1	target
Nesiritide	Atrial natriuretic peptide receptor 2	target
Nesiritide	Atrial natriuretic peptide receptor 3	target
Desmoteplase	Plasminogen	target
Tigapotide	40S ribosomal protein SA	target
Abaloparatide	Parathyroid hormone/parathyroid hormone-related peptide receptor	target
Leptin	Leptin receptor	target
Elafin	Neutrophil elastase	target
Elafin	Myeloblastin	target
Elafin	Myeloperoxidase	enzyme
Interferon alfa	Interferon alpha/beta receptor 1	target
Interferon alfa	Cytochrome P450 1A2	enzyme
Glatiramer	HLA class II histocompatibility antigen, DRB1-1 beta chain	target
Glatiramer	HLA class II histocompatibility antigen, DRB1-15 beta chain	target
Glatiramer	HLA class II histocompatibility antigen, DRB1-4 beta chain	target
Keyhole limpet hemocyanin	Interleukin-2	target
Cintredekin besudotox	Interleukin-13	target
Romiplostim	Thrombopoietin receptor	target
Regramostim	Granulocyte-macrophage colony-stimulating factor receptor subunit alpha	target
Regramostim	GM-CSF receptor alpha subunit	target
Regramostim	Cholinesterase	enzyme
Corticorelin	Dopamine beta-hydroxylase	enzyme
Tifuvirtide	Plasma serine protease inhibitor	target
Thrombomodulin Alfa	Coagulation factor V	target
Thrombomodulin Alfa	Prothrombin	target
Sar9, Met (O2)11-Substance P	Cytochrome P450 19A1	enzyme
Sar9, Met (O2)11-Substance P	Cholinesterase	enzyme
Sar9, Met (O2)11-Substance P	Prostaglandin G/H synthase 2	enzyme
Pegdinetanib	Vascular endothelial growth factor receptor 2	target
CTCE-0214	Stromal cell-derived factor 1	target
IRL-1620	Endothelin B receptor	target
Nelipepimut-S	HLA class I histocompatibility antigen, A-2 alpha chain	target
Nelipepimut-S	HLA class I histocompatibility antigen, A-3 alpha chain	target
Lanoteplase	Urokinase plasminogen activator surface receptor	target
Lanoteplase	Fibrinogen alpha chain	target
Lanoteplase	Kallikrein-1	target
Lanoteplase	Laminin subunit alpha-5	target
Lanoteplase	Coagulation factor X	target
Lanoteplase	Fibronectin	target
Lanoteplase	Plasminogen activator inhibitor 2	target
Lanoteplase	Tetranectin	target
Lanoteplase	Keratin, type II cytoskeletal 8	target
Lanoteplase	Annexin A2	target
Lanoteplase	Laminin subunit beta-1	target
Lanoteplase	Laminin subunit gamma-1	target
Lanoteplase	Laminin subunit alpha-1	target
Lanoteplase	Calreticulin	target
Lanoteplase	Calnexin	target
Lanoteplase	Prolow-density lipoprotein receptor-related protein 1	target
Lanoteplase	Laminin subunit alpha-3	target
Rilonacept	Interleukin-1 beta	target
Rilonacept	Interleukin-1 alpha	target
Rilonacept	Interleukin-1 receptor antagonist protein	target
Endostatin	72 kDa type IV collagenase	target
Endostatin	Matrix metalloproteinase-9	target
Endostatin	Collagenase 3	target
Endostatin	Focal adhesion kinase 1	target
Endostatin	E-selectin	target
Endostatin	Cytochrome P450 19A1	enzyme
Onercept	Tumor necrosis factor	target
AMGN-0007	肿瘤坏死因子配体超家族成员11	target
Thrombopoietin	Thrombopoietin receptor	target
Atibuclimab	Monocyte differentiation antigen CD14	target
Pasireotide	Somatostatin receptor type 1	target
Pasireotide	Somatostatin receptor type 2	target
Pasireotide	Somatostatin receptor type 3	target
Pasireotide	Somatostatin receptor type 5	target
Pasireotide	Cytochrome P450 3A4	enzyme
Belatacept	T-lymphocyte activation antigen CD86	target
Belatacept	T-lymphocyte activation antigen CD80	target
Lanreotide	Somatostatin receptor type 2	target
Lanreotide	Somatostatin receptor type 5	target
Lanreotide	Cytochrome P450 3A4	enzyme
Triptorelin	Gonadotropin-releasing hormone receptor	target
DADLE	Solute carrier organic anion transporter family member 1B1	transporter
DPDPE	Solute carrier organic anion transporter family member 1B3	transporter
Tesamorelin	Growth hormone-releasing hormone receptor	target
Aflibercept	Vascular endothelial growth factor A	target
Aflibercept	Placenta growth factor	target
Aflibercept	Vascular endothelial growth factor B	target
Corticorelin ovine triflutate	Corticotropin-releasing factor receptor 1	target
Somatostatin	Somatostatin receptor type 1	target
Somatostatin	Somatostatin receptor type 2	target
Somatostatin	Somatostatin receptor type 3	target
Somatostatin	Somatostatin receptor type 4	target
Somatostatin	Somatostatin receptor type 5	target
Somatostatin	P-glycoprotein 1	transporter
Somatostatin	Cytochrome P450 3A4	enzyme
Ancestim	Mast/stem cell growth factor receptor Kit	target
甲氧基聚乙烯glycol-epoetinβ	Erythropoietin receptor	target
Turoctocog alfa	Coagulation factor IX	target
Turoctocog alfa	Coagulation factor X	target
Turoctocog alfa	Prothrombin	target
Chorionic Gonadotropin (Human)	Lutropin-choriogonadotropic hormone receptor	target
Polaprezinc	Tumor necrosis factor	target
Polaprezinc	Interleukin-6	target
Polaprezinc	Interleukin-3	target
Polaprezinc	Superoxide dismutase [Cu-Zn]	enzyme
Polaprezinc	Heme oxygenase 1	enzyme
Polaprezinc	Superoxide dismutase [Mn], mitochondrial	enzyme
Polaprezinc	Glutathione S-transferase theta-1	enzyme
Polaprezinc	Glutathione peroxidase 1	enzyme
Polaprezinc	Peroxiredoxin-1	enzyme
Polaprezinc	Peroxiredoxin-5, mitochondrial	enzyme
Polaprezinc	Vascular endothelial growth factor receptor 1	target
Polaprezinc	Beta-nerve growth factor	target
Polaprezinc	Platelet-derived growth factor receptor beta	target
Polaprezinc	Heat shock protein HSP 90-alpha	target
Polaprezinc	Heat shock protein HSP 90-beta	target
Conestat alfa	Complement C1r subcomponent	target
Conestat alfa	Complement C1s subcomponent	target
Conestat alfa	Plasma kallikrein	target
Conestat alfa	Coagulation factor XII	target
Conestat alfa	Prothrombin	target
Conestat alfa	Coagulation factor XI	target
Conestat alfa	Tissue-type plasminogen activator	target
Antihemophilic factor (recombinant), PEGylated	von Willebrand factor	target
Antihemophilic factor (recombinant), PEGylated	von Willebrand factor	carrier
Technetium Tc-99m nofetumomab merpentan	Epithelial cell adhesion molecule	target
Technetium Tc-99m nofetumomab merpentan	B-lymphocyte antigen CD20	target
Protirelin	Thyrotropin Releasing Hormone Receptor	target
Secretin human	Secretin receptor	target
Desirudin	Carboxypeptidase A1	enzyme
Thrombin	Proteinase-activated receptor 1	target
Thrombin	Proteinase-activated receptor 4	target
Thrombin	Coagulation factor XI	target
Thrombin	Coagulation factor XIII A chain	target
Thrombin	Coagulation factor XIII B chain	target
Thrombin	Fibrinogen alpha chain	target
Thrombin	Fibrinogen beta chain	target
Thrombin	Fibrinogen gamma chain	target
Thrombin	Coagulation factor V	target
Thrombin	Coagulation factor VIII	target
Prothrombin	Fibrinogen alpha chain	target
Prothrombin	Fibrinogen beta chain	target
Prothrombin	Coagulation factor XIII A chain	target
Prothrombin	Carboxypeptidase B2	target
Prothrombin	Coagulation factor X	enzyme
Dibotermin alfa	Bone morphogenetic protein receptor type-1A	target
Dibotermin alfa	Bone morphogenetic protein receptor type-2	target
Angiotensin II	Type-1 angiotensin II receptor	target
Ulocuplumab	C-X-C chemokine receptor type 4	target
Von Willebrand factor human	Coagulation factor VIII	target
Von Willebrand factor human	Collagen alpha-1(I) chain	target
Von Willebrand factor human	A disintegrin and metalloproteinase with thrombospondin motifs 13	enzyme
Von Willebrand factor human	Asialoglycoprotein receptor 1	target
Von Willebrand factor human	Prolow-density lipoprotein receptor-related protein 1	target
Lenograstim	Granulocyte colony-stimulating factor receptor	target
Coagulation factor VII human	Tissue factor	target
Coagulation factor VII human	Coagulation factor X	target
Coagulation factor VII human	Coagulation factor IX	target
Anti-inhibitor coagulant complex	Coagulation factor X	target
Anti-inhibitor coagulant complex	Prothrombin	target
Anti-inhibitor coagulant complex	Fibrinogen alpha chain	target
Anti-inhibitor coagulant complex	Fibrinogen beta chain	target
Anti-inhibitor coagulant complex	Coagulation factor XIII A chain	target
Anti-inhibitor coagulant complex	Coagulation factor V	target
Anti-inhibitor coagulant complex	Coagulation factor VIII	target
Anti-inhibitor coagulant complex	Coagulation factor VII	target
Coagulation Factor IX Human	Coagulation factor X	target
Coagulation Factor IX Human	Coagulation factor XI	target
Coagulation Factor IX Human	Coagulation factor VII	target
Coagulation Factor IX Human	Coagulation factor VIII	target
Coagulation Factor IX Human	Prothrombin	target
Coagulation Factor IX Human	Prolow-density lipoprotein receptor-related protein 1	target
Coagulation Factor IX Human	Vitamin K-dependent gamma-carboxylase	target
Cerliponase alfa	Cation-independent mannose-6-phosphate receptor	target
Antihemophilic factor human	Coagulation factor IX	target
Antihemophilic factor human	Coagulation factor X	target
Antihemophilic factor human	Vitamin K-dependent protein C	enzyme
Lipegfilgrastim	Granulocyte colony-stimulating factor receptor	target
Albutrepenonacog alfa	Coagulation factor X	target
Albutrepenonacog alfa	Coagulation factor VIII	enzyme
Cenegermin	High affinity nerve growth factor receptor	target
Nonacog beta pegol	Coagulation factor VII	target
Nonacog beta pegol	Coagulation factor VIII	target
Nonacog beta pegol	Coagulation factor X	target
Moroctocog alfa	Coagulation factor X	target
Moroctocog alfa	Phytanoyl-CoA dioxygenase, peroxisomal	target
Moroctocog alfa	Coagulation factor IX	target
Moroctocog alfa	Asialoglycoprotein receptor 2	target
Moroctocog alfa	78 kDa glucose-regulated protein	target
Moroctocog alfa	Calreticulin	target
Moroctocog alfa	Calnexin	target
Moroctocog alfa	Protein ERGIC-53	target
Moroctocog alfa	Prolow-density lipoprotein receptor-related protein 1	target
Moroctocog alfa	Multiple coagulation factor deficiency protein 2	target
Moroctocog alfa	von Willebrand factor	target
Moroctocog alfa	Prothrombin	enzyme
Moroctocog alfa	Vitamin K-dependent protein C	enzyme
Andexanet alfa	Tissue factor pathway inhibitor	target
Lypressin	Vasopressin V1a receptor	target
Lypressin	Vasopressin V2 receptor	target
Lypressin	Vasopressin V1b receptor	target
Lypressin	Canalicular multispecific organic anion transporter 1	transporter
Sutimlimab	Complement C1s subcomponent	target
Toripalimab	Programmed cell death protein 1	target
Interferon alfa-2c	Cytochrome P450 1A2	enzyme
Tirzepatide	Glucagon-like peptide 1 receptor	target
Tirzepatide	Gastric inhibitory polypeptide	target
Tirzepatide	Serum albumin	carrier
Tebentafusp	Melanocyte protein PMEL	target
Padeliporfin	Solute carrier organic anion transporter family member 1B1	transporter
Padeliporfin	Solute carrier organic anion transporter family member 1B3	transporter
Padeliporfin	Serum albumin	carrier
Spesolimab	Interleukin-1 receptor-like 2	target
Zilucoplan	Complement C5	target
Anti-SARS-CoV-2 REGN-COV2	Spike glycoprotein	target
Brexucabtagene autoleucel	淋巴球抗原CD19	target
Sintilimab	Programmed cell death protein 1	target
Envafolimab	Programmed cell death 1 ligand 1	target
Etesevimab	Spike glycoprotein	target
Rurioctocog alfa pegol	von Willebrand factor	target
Rurioctocog alfa pegol	Coagulation factor VIII	target
Loncastuximab tesirine	淋巴球抗原CD19	target
Loncastuximab tesirine	P-glycoprotein 1	transporter
Loncastuximab tesirine	Cytochrome P450 3A4	enzyme
Loncastuximab tesirine	Cytochrome P450 3A5	enzyme
Vilobelimab	Complement C5	target
Narsoplimab	Mannan-binding lectin serine protease 2	target
Pam2csk4	Toll-like receptor 6	target
Pam2csk4	Toll-like receptor 2	target
Idecabtagene vicleucel	Tumor necrosis factor receptor superfamily member 17	target
Budigalimab	Programmed cell death protein 1	target
Tisotumab vedotin	Cytochrome P450 3A4	enzyme
Tisotumab vedotin	Tissue factor	target
Tisotumab vedotin	P-glycoprotein 1	transporter
Bebtelovimab	Spike glycoprotein	target